**EXHIBIT      10.4**

**AMENDED      AND RESTATED LICENSE AGREEMENT**

**Agreement**

**INEX      PHARMACEUTICALS CORPORATION**

**INEX**

**HANA      BIOSCIENCES, INC.**

**Hana**

| A.   | On                May 6, 2006, INEX (as hereinafter defined) and Hana entered into                a License                Agreement (as hereinafter defined) to govern the Parties’ respective                rights and obligations in respect of Hana’s use in the Hana Field (as                hereinafter defined), of Patents (as hereinafter defined) and Technology                (as hereinafter defined). |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| B.   | On                May 6, 2006, INEX and Hana entered into a Transaction Agreement (as                hereinafter defined). Pursuant to which Section 6.7 of the Transaction                Agreement, INEX agreed to make commercially reasonable efforts to                obtain                the consent of Aradigm (as hereinafter defined) to the assignment                by INEX                to Hana of the BCCA Patents (as hereinafter defined) licensed by                INEX to                Aradigm for use in the pulmonary delivery of Ciprofloxacin, and Hana                agreed to license the BCCA Patents back to INEX for use outside the                Hana                Field and remain liable to INEX for all milestone, royalty and                sublicensing payments which Hana would otherwise have made to INEX                in                respect of the BCCA Patents had the assignment by INEX to Hana not                taken                place. |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| C.   | Pursuant                to Section 6.8 of the Transaction Agreement, INEX agreed to make                commercially reasonable efforts to obtain the consent of MD Anderson                (as                hereinafter defined) to the assignment by INEX to Hana of the MD                Anderson                License (as hereinafter defined), Sarris Patents (as hereinafter                defined),                and Thomas Patents (as hereinafter defined), and Hana agreed to license                the Sarris Patents and Thomas Patents back to INEX for use outside                the                Hana Field and remain liable to INEX for all milestone, royalty and                sublicensing payments which Hana would otherwise have made to INEX                in                respect of the Sarris Patents and Thomas Patents had the assignment                by                INEX to Hana not taken place. |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| D.   | The                Parties are herewith entering into this Amended and Restated License                Agreement to: (i) to effect the termination of the license by INEX                to Hana                of the MD Anderson Patents, and the termination of all rights,                responsibilities and obligations of Hana associated therewith; (ii)                to                affirm the continuation of the license by INEX to Hana of the Licensed                Patents (as hereinafter defined) for use in the Hana Field, and to                affirm                the continuation of all rights, responsibilities and obligations                of Hana                associated therewith; and (iii) to effect the license by Hana to                INEX of                the MD Anderson Patents for use outside the Hana Field upon the terms                and                conditions contained herein; all as contemplated by Section 6.8 of                the                Transaction Agreement. |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| E.   | On                even date hereof, the Parties are entering into an Assignment and                Novation                Agreement with MD Anderson to effect the assignment by INEX to Hana                of the                MD Anderson License and the MD Anderson Patents as contemplated by                Section                6.8 of the Transaction Agreement. |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      1**
**INTERPRETATION**

**1.1  **
**Definitions**

| 1.1.1                | “**Abandoning                Party**”                shall have the meaning set forth in Section                8.5.1. |
|---------------------------|------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.2                | “**Adverse                Drug Event**”                means any noxious, unintended, or untoward medical occurrence in                a patient                or clinical investigation subject associated with the use of a medicinal                or investigational product, whether or not related to the medicinal                or                investigational product. |
|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.3                | “**Affiliate**”                means, with respect to any Person, any Person directly or indirectly                controlled by, controlling or under common control with such Person.                For                the purposes of this definition, “control” shall mean direct or indirect                beneficial ownership of 50% or greater interest in the voting power                of                such Person or such other relationship as, in fact constitute actual                control. |
|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.4                | “**Agreement**”                means this Amended and Restated License Agreement and all exhibits                attached hereto. |
|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.5                | “**Applicable                Laws**”                means all applicable federal, provincial, state and local laws,                ordinances, rules and regulations of any kind whatsoever in the Territory,                including, without limitation, pharmaceutical and environmental rules                and                regulations, including cGMP Requirements, GCP Requirements, GLP                Requirements and the General Biological Products Standards of the                FDA, and                the Federal Food, Drug and Cosmetic Act, as amended, or any successor                act                thereto (“**FDCA**”). |
|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.6                | “**Aradigm**”                means Aradigm Corporation, a company duly incorporated pursuant to                the                laws of the State of California, and having its principal place of                business at 3929 Point Eden Way, Hayward, CA 94545,                U.S.A. |
|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.7                | “**Aradigm                License**”                means the license agreement dated December 8, 2004 between Aradigm                and                INEX. |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.8                | “**Assessed                Value**”                shall have the meaning set forth in Section                3.6.6(b). |
|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.9                | “**Assigned                Patents**”                mean the MD Anderson Patents listed in **Exhibit                1.1.9**                attached hereto. |
|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.1.10   | “**Bankruptcy                Action**”                shall have the meaning set forth in Section                14.3.3. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.11                | “**BCCA**”                means the British Columbia Cancer                Agency. |
|----------------------------|------------------------------------------------------------------------------------------------|

| 1.1.12   | “**BCCA                Agreements**”                means the Research Project Agreement between INEX (formerly Lipex                Pharmaceuticals, Inc.) and the British Columbia Cancer Agency dated                February 25, 1993 and terminated May 6, 2002. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.13   | “**BCCA                Patents**”                means: |
|--------------------|---------------------------------------------------------------------|

| (a)   | the                egg sphingomyelin patents assigned by the BCCA to INEX;                and |
|-----------------|-----------------------------------------------------------------------------------------------|

| (b)   | any                and all counterparts of the foregoing, including all divisionals,                provisionals, non-provisionals, and continuations, and all patents                issuing                on any of the foregoing and any foreign counterparts thereof, together                with all registrations, reissues, re-examinations, supplemental protection                certificates, additions, renewals or extensions thereof and any foreign                counterparts thereof; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | the                BCCA (including royalty rights) under the terms and conditions of                the BCCA                Agreements; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | INEX                (including milestone, Licensing/Sublicensing Revenue and royalty                rights)                under the terms and conditions of this Agreement;                and |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | Aradigm                under the terms and conditions of the Aradigm                License. |
|-----------------|----------------------------------------------------------------------------------------------|

| 1.1.14                | “**Business                Day**”                means any day other than a day which is a Saturday, a Sunday or a                statutory holiday in British Columbia                or                California. |
|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.15   | “**Calendar                Quarter**”                means each of the three-month periods ending on March 31, June 30,                September 30 or December 31. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.16                | “**cGMP                Requirements**”                means the current Good Manufacturing Practices standards required                by the                FDA (as set forth in the FDCA), the Therapeutic Products Directorate                Organization of Health Canada ("**TPD**"),                and the European Medicines Evaluation Agency ("**EMEA**")                and any other jurisdiction as mutually agreed between the Parties                together                with their applicable regulations, policies or guidelines which are                in                effect for the manufacture and testing of pharmaceutical materials,                active                ingredients, or excipients for use in Phase I, Phase II, and Phase                III                clinical trials, as applicable. |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.17   | “**Clinical                Activity**”                and “**Clinical                Activities**”                mean any one or more of the activities associated with drug testing                in                humans, including trial design and execution, payment of investigators’,                institutional, and contractors’ fees, drug distribution and                accountability, analytical testing, data management, statistical                analysis,                adverse event reporting, and scientific publication, performed in                pursuit                of the Development and Commercialization of a                Product. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.18                | “**Clinical                Trial Material**”                means labeled and packaged Sphingosomal Vincristine, Sphingosomal                Vinorelbine and/or Sphingosomal Topotecan, and any component(s) thereof,                used or to be used, in clinical                trials. |
|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.1.19   | “**Closing                Payment**”                means an aggregate of One Million Five Hundred Thousand Dollars                ($1,500,000) in funds held in escrow paid by Hana to INEX pursuant                to the                terms and conditions of the Transaction                Agreement. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.20                | “**Closing                Shares**”                means the number of shares of Common Stock determined by dividing Ten                Million Dollars ($10,000,000) by the FMV of the Common Stock as of                March 16, 2006, paid by Hana to INEX pursuant to the terms and conditions                of the Transaction Agreement. |
|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.21   | “**Commercialize**”                and “**Commercialization**”                mean the activities customarily associated with sales of pharmaceutical                products including without limitation, DDMAC Activities, price and                reimbursement negotiations, pre-launch and launch activities, marketing,                sales, distribution, post-approval Clinical Activities, the development,                prosecution, registration and maintenance of trademarks, trade names                and                domain names, and Pharmacovigilance in each country in the                Territory. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.22   | “**Commercially                Reasonable Efforts**”                means those efforts and resources that Hana would use were it developing,                promoting and detailing its own pharmaceutical products which are                of                similar market potential as the Products, taking into account product                labeling, market potential, past performance, economic return, the                regulatory environment and competitive market conditions in the                therapeutic area, all as measured by the facts and circumstances                at the                time such efforts are due. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  1.1.23   | “**Common                Stock**”                means the common stock of Hana, par value $0.001 per                share. |
|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.24   | “**Confidential                Information**”                means all information, knowledge or                data: |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------|

| (a)   | of                an intellectual, technical, scientific or industrial nature, patentable                or                otherwise, in which a Party has a proprietary or ownership interest,                including, without limitation, technical data, drawings, photographs,                scans, specifications, standards, analytical methods, techniques,                manuals,                reports, formulas, compilations, processes, information, lists, trade                secrets, computer software, programs, devices, equipment, concepts,                inventions, designs, and know-how (including                Technology); |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | pertaining                to the business and affairs of a Party, including, without limitation,                financial information, marketing, manufacturing and commercial strategies,                patent positioning, business plans, strategies and developments,                including                any negative developments; or |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | provided                or disclosed to a Party by Third Parties subject to restrictions                on use or                disclosure, whether oral or written, furnished by the disclosing                Party to                the receiving Party or any of its Representatives, whether furnished                or                prepared before or after the Effective Date of the Definitive Agreements,                and includes all analyses, compilations, data, studies, reports or                other                documents based upon or including any of such information, data or                knowledge and, in all cases, all copies and tangible embodiments                thereof,                in whatever form or medium; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (a)   | can                be demonstrated by the receiving Party by written record to have                been                known or otherwise available to the receiving Party prior to the                disclosure by the disclosing Party; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | can                be demonstrated by the receiving Party by written record to have                been in                the public domain at the time of                disclosure; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | after                disclosure, can be demonstrated by the receiving Party by written                record                to have subsequently become part of the public domain other than                as a                consequence of a breach of this Confidential Disclosure Agreement                by the                receiving Party or its                Representatives; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | after                disclosure, can be demonstrated by the receiving Party by written                record                to have been subsequently provided to the receiving Party by a Third                Party, but only to the extent that the receiving Party can demonstrate                that such disclosure does not violate any obligations of the Third                Party                to the disclosing Party; or |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | the                receiving Party can demonstrate by written records results from research                and development activity conducted by the receiving Party or any                of its                Affiliates independently and in advance of disclosure by the other                Party                thereof. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.25   | “**Damages**”                means any losses, liabilities, obligations, damages, penalties, fines,                claims, demands, actions, suits, costs and expenses of any nature                whatsoever, excluding indirect, special or consequential damages,                but                including, without limitation, legal fees, charges and disbursements,                and                the indirect, special or consequential damages of Third Parties for                which                a Party, INEX Indemnitees or Hana Indemnitees, as the case may be,                is                responsible. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.26   | “**DDMAC                Activities**”                mean all activities performed in accordance with the requirements                of the                Division of Drug Marketing, Advertising and Communications, Center                for                Drug Evaluation and Research of the FDA, and the Office of the Inspector                General of the Department of Health and Human Services of the United                States. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.27   | “**Definitive                Agreements**”                mean the Asset Purchase Agreement, Elan Assignment and Novation Agreement,                License Agreement, Service Agreement, UBC Sublicense Agreement;                Transaction Agreement, and Registration Rights                Agreement. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.28                | “**Designated                EU States**”                means any one of Germany, the United Kingdom, Italy, France or                Spain. |
|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.29   | “**Develop**”                and “**Development**”                means: |
|--------------------|--------------------------------------------------------------------------------------------------|

| (a)   | all                activities set forth in the Development Plan;                and |
|-----------------|-------------------------------------------------------------------------------------|

| (b)   | all                activities necessary to obtain and maintain Regulatory Approvals                in each                country in the Territory, including Clinical Activities, Regulatory                Activities, Technical Transfer and Manufacturing                activities. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.1.30                | “**Development                Plan**”                means the development plan for seeking Regulatory Approvals for each                Product in the Territory during the initial twelve (12) months following                the Effective Date of the Definitive Agreements, together with a                corresponding budget accounting for the anticipated costs to be expended                or incurred by Hana in conducting the Development. The Development                Plan                and any amendments thereto adopted in accordance with Article 4 will                form                a part of this Agreement. |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.31   | “**Discontinued                Patent**”                shall have the meaning set forth in Section                8.5.3. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.32                | “**Dispute**”                shall have the meaning set forth in Section                13.1.1. |
|----------------------------|-------------------------------------------------------------------------------------------------------------|

| 1.1.33   | “**Dollars**”                or “**$**”                shall mean the lawful money of the United States of                America. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.34                | “**Effective                Date of the Definitive Agreements**”                means May 6, 2006. |
|----------------------------|----------------------------------------------------------------------------------------------------------------|

| 1.1.35                | “**Excess                Amount**”                shall have the meaning set forth in Section                9.2.6. |
|----------------------------|---------------------------------------------------------------------------------------------------------------------------------|

| 1.1.36                | “**Fair                Market Value**”                for the purposes of Sections 1.1.69 and 1.1.56, means the highest                price,                expressed in dollars, that an asset (whether tangible or intangible)                would                bring in an open and unrestricted market, between a willing buyer                and a                willing seller who are both knowledgeable, informed, and prudent,                and who                are acting independently of each                other. |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.37   | “**FDA**”                means the Food and Drug Administration of the United States of                America. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------|

| 1.1.38                | “**FMV**”                means the quotient resulting from dividing (A) the sum of the value                of all                trades for each of the twenty (20) trading days immediately preceding                the                FMV reference date, by (B) the aggregate volume of all trades of                shares of                Common Stock during such twenty trading day period, in each case                as                reported in the principal exchange or stock market on which the Common                Stock is then listed. |
|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.39   | “**FTE                Rate**”                means the fully burdened rate established by INEX for the services                of a                INEX employee or consultant providing IP Services which for the first                year                from the Effective Date of the Definitive Agreements, is $[***] based                on                1,800 employee hours per year, or pro-rata portion thereof; provided                however, that on each anniversary of the Effective Date of the Definitive                Agreements, the FTE Rate shall be adjusted by a percentage equal                to the                net change in the Consumer Price Index (All Items) for the province                of                British Columbia for the twelve (12) month period ending with December                of                the calendar year immediately preceding such anniversary                date. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.40   | “**GCP                Requirements**”                or “**Good                Clinical Practices**”                means the then current standards for clinical trials for pharmaceuticals                as required by the FDA, the TPD and the equivalent Regulatory Authority                elsewhere in the Territory and as applicable, the policies and guidelines                of the International Conference on Harmonization in effect for the                clinical testing of pharmaceutical                materials. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.41                | “**GLP                Requirements**”                or “**Good                Laboratory Practices**”                means the current Good Laboratory Practices standards required by                the FDA,                the TPD and the equivalent Regulatory Authority elsewhere in the                Territory                in effect for the testing of pharmaceutical materials as applied                to raw                materials and finished products. |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.42   | “**Hana                Field**”                means all uses of the Products. |
|--------------------|--------------------------------------------------------------------------------------------|

----

|             1.1.43   | “**Hana                Indemnitees**”                shall have the meaning set forth in Section                12.2. |
|--------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|

| 1.1.44   | “**Hana                Intellectual Property**”                means: |
|--------------------|-----------------------------------------------------------------------------------|

| (a)   | all                Intellectual Property Rights patents and patent applications (whether                complete or incomplete or whether filed or unfiled), including                registrations, in any jurisdiction world-wide, as well as any patents                and                patent applications to which Hana has accepted an assignment or license                during the term of this Agreement; and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | all                Confidential Information owned or controlled by Hana at any time                during                the Term of this Agreement. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.45   | “**IND**”                means an Investigational New Drug application in accordance with                the rules                and regulations of the FDA. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.46   | “**Indemnitee**”                shall have the meaning set forth in Section                12.3. |
|--------------------|--------------------------------------------------------------------------------------------------------------|

| 1.1.47   | “**Indemnitor**”                shall have the meaning set forth in Section                12.3. |
|--------------------|--------------------------------------------------------------------------------------------------------------|

| 1.1.48   | “**INEX                Indemnitees**”                shall have the meaning set forth in Section                12.1. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------|

| 1.1.49   | “**Intellectual                Property Rights**”                means all intellectual property rights subject to protection by                intellectual property laws in any country of the world, arising under                statutory or common law, contract, or otherwise, and whether or not                perfected, including without limitation, all (a) patents, reissues                of and                re-examined patents, and patent applications, whenever filed and                wherever                issued, including without limitation, continuations,                continuations-in-part, substitutes and divisions of such applications                and                all priority rights resulting from such applications; (b) rights                associated with works of authorship including without limitation                copyrights, moral rights, copyright applications, copyright registrations,                synchronization rights, mask work rights, mask work applications,                mask                work registrations; (c) rights associated with trademarks, service                marks,                trade names, logos, trade dress, goodwill and the applications for                registration and registrations thereof; (d) rights relating to the                protection of trade secrets and confidential information (e) rights                analogous to those set forth in this Section and any and all other                proprietary rights relating to intangible property; and (f) divisions,                continuations, renewals, reissues and extensions of the foregoing                (as and                to the extent applicable) now existing, hereafter filed, issued or                acquired. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.50   | “**IP                Committee**”                shall have the meaning set forth in Section                8.1. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------|

| 1.1.51   | “**IP                Services**”                means such services as Hana deems reasonably necessary, desirable                or                helpful to evidence, maintain, protect or enforce Hana’s rights as set                forth under the Services Agreement, and as further defined in Section                8.6.2. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.52   | “**License**”                means an agreement between Hana and its Affiliate or between Hana                and a                Third Party, to whom Hana has granted a license of the rights granted                by                INEX to Hana in respect of one or more of the                following: |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | the                Assigned Patents; and |
|-----------------|------------------------------------------|

| (b)   | that                portion of the Technology that relates to the Assigned                Patents. |
|-----------------|----------------------------------------------------------------------------------------------------|

----

| 1.1.53   | “**License                Agreement**”                means the License Agreement dated May 6, 2006 between INEX and                Hana. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.54   | “**Licensed                Patents**”                means all right, title and interest in and to the inventions described                in: |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | with                the exception of the Assigned Patents, the patents and patent applications                existing on the Effective Date of the Definitive Agreements that                were                originally assigned to INEX and are listed in **Exhibit                1.1.54**                attached hereto; and |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | any                and all patents and patent applications assigned or licensed by INEX                to                Hana after the effective date of this Agreement and during the Term                of                this Agreement that are necessary and useful in the Development or                Commercialization of the Products, subject to the terms and limitations                of                any agreement related to such patents and applications;                and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | any                and all counterparts of the foregoing, including all divisionals,                provisionals, non-provisionals, and continuations, and all patents                issuing                on any of the foregoing and any foreign counterparts thereof, together                with all registrations, reissues, re-examinations, supplemental protection                certificates, additions, renewals or extensions thereof and any foreign                counterparts thereof. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.55   | “**Licensee**”                means an Affiliate or Third Party to whom Hana has granted a License.                Without limiting the generality of the foregoing, a Licensee shall                be                deemed to include an Affiliate or Third Party who is granted a License                hereunder by Hana pursuant to the terms of the outcome or settlement                of                any infringement or threatened infringement or threatened infringement                action. Without limiting the generality of the foregoing, a Licensee                shall                be deemed to include any Affiliate or Third Party who is granted                a License                hereunder by Hana pursuant to the terms of the outcome or settlement                of                any infringement or threatened infringement                action. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.56   | “**Licensing/Sublicensing                Revenue**”                means all transaction closing payments, milestone payments, license                fees                and any other pre-Commercialization payments (excluding royalties,                sales                revenue, sales commissions and any monies and proceeds derived from                the                sale of licensed or sublicensed Product) payable to, collected or                received                by Hana or its Affiliates pursuant to each License or Sublicense                entered                into in respect of:  |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | the                Technology; |
|-----------------|--------------------------------|

| (b)   | the                Licensed Patents; and/or |
|-----------------|---------------------------------------------|

| (c)   | the                Assigned Patents. |
|-----------------|--------------------------------------|

| (d)   | loans                to Hana or its Affiliates by a Licensee or Sublicensee relating to                the                Patents and Technology, except to the extent that the interest charged                for                such loan is less than Fair Market Value (in which case only such                difference between the interest rate charged to Hana and the interest                rate                at Fair Market Value shall constitute Licensing/Sublicensing Revenue)                or                to the extent that the principal of a loan is forgiven (in which                case only                such forgiven amount shall constitute Licensing/Sublicensing Revenue);                or |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (e)   | equity                investments in Hana by a Licensee or Sublicensee, or equity of the                Licensee or Sublicensee relating to the Patents and Technology, except                to                the extent that such investment are made at greater than Fair Market                Value                (in which case only the excess premium shall constitute                Licensing/Sublicensing Revenue). For the purposes of this Section,                if the                shares of either Hana or its Licensee or Sublicensee are not listed                on any                stock exchange, the Fair Market Value shall be based on the price                at which                shares of either Hana or its Licensee or Sublicensee, as the case                may be,                have been issued to investors (who are not industry-related strategic                investors or collaborative research partners) in the then most recent                bona                fide arm’s length private placement financing completed within the                preceding twelve (12) months having gross proceeds of at least Ten                Million ($10,000,000). If no such private placement financing has                been completed, the Parties shall appoint a mutually acceptable Person                as                an independent evaluator, and if the Parties cannot agree on an evaluator,                the Fair Market Value shall be determined as provided in Article                13;                or |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | An                exchange of rights, assets, liabilities or other interest of any                kind,                except to the extent that the economic benefit conferred upon Hana                or its                Affiliates by reason of such exchange exceeds the Fair Market Value                of the                consideration which would have been paid by Hana or its Affiliates                for                such rights, assets, liabilities or interests, as determined by:                (i) the                mutual agreement of the Parties following the application of U.S.                GAAP, or                failing mutual agreement; (ii) the binding decision of a mutually                appointed independent Third Party banker or valuator familiar with                the                pharmaceutical industry. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.57   | “**Litigating                Party**”                shall have the meaning set forth in Section                9.2.5. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.58   | “**Major                Markets**”                means the countries of the United States of America, Germany, the                United                Kingdom, Italy, France, Spain. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.59   | “**Manufacture**”,                “**Manufactured**”                and “**Manufacturing**”                means all or a portion of the activities of Hana, INEX, its Affiliates                or                their respective Third Party contractors associated with the                manufacturing, filling, sampling, testing, handling, labeling, packaging                and storage of Material and all                work-in-progress. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.60   | “**Marqibo**”                is Hana’s trade name for Sphingosomal                Vincristine. |
|--------------------|------------------------------------------------------------------------------------------------------------------|

| 1.1.61   | “**Material**”                means all compounds, materials, substances, components or consumables                sourced or Manufactured by INEX, Hana or any of their respective                Third                Party contractors to produce Clinical Trial Material                (including Clinical Trial Material), and Product for commercial sale,                but                excluding machinery and equipment. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.1.62   | “**Maximum                Issuance Amount**”                shall have the meaning set forth in Section                3.4. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.63   | “**MD                Anderson**”                means the University of Texas MD Anderson Cancer                Center. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.64   | “**MD                Anderson Assignment and Novation Agreement**”                means the Assignment and Novation Agreement between MD Anderson,                INEX and                Hana to effect the assignment by INEX to Hana of the MD Anderson                License. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.65   | “**MD                Anderson License**”                means the Patent and Technology License Agreement made as of February                14,                2000 between the Board of Regents of the University of Texas System                on                behalf of the University of Texas MD Anderson Cancer Center and INEX,                amended as of August 15, 2000. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.66   | “**MD                Anderson Patents**”                means the Sarris Patents and Thomas Patents. |
|--------------------|------------------------------------------------------------------------------------------------------------------|

| 1.1.67   | “**Method                Transfer**”                means, in respect of the Services, the transfer by INEX and/or INEX’s                Third Party contractors to Hana, Hana’s Third Party contractors and/or                INEX’s Third Party contractors, of the methods for the testing of Material                pursuant to Method Transfer protocols mutually agreed between the                Parties,                and shall include, without limitation, performance of Method Transfer                qualification. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.68   | “**NDA**”                means a New Drug Application in accordance with the rules and regulations                of the FDA. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.69   | “**Net                Sales**”                means the aggregate United States dollar equivalent of gross revenues                invoiced by Hana and its Affiliates and Licensees and Sublicensees                from or                on account of the sale of Product to Third Parties, in any given                calendar                year, less deductions actually allowed or specifically allocated                to                Product and actually incurred by Hana or its Affiliates or Licensees                or                Sublicensees using US GAAP and reasonable practices with respect                to sales                of all Product, consistently applied, for the                following: |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | credits                or allowances, if any, actually granted on account of recalls, rejection                or return of Product; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | insurance,                freight or other transportation costs incurred in shipping Product                to such                Third Parties; and |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | excise                taxes, sales taxes, value added taxes, consumption taxes, customs                and                other duties or other taxes or other governmental charges imposed                upon and                paid or allowed with respect to the production, importation, use                or sale                of Product (excluding income or franchise taxes of any kind);                (collectively, the “**Permitted                Deductions**”).                The foregoing definition is subject to the                following: |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | no                deductions shall be made for any item of cost incurred by Hana, its                Affiliates or Licensees or Sublicensees in preparing, Manufacturing,                shipping or selling Product except as permitted pursuant to Sections                1.1.69(a), 1.1.69(b) and 1.1.69(c)                inclusive; |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (e)   | Net                Sales shall not include transfer between any of Hana and any of its                Affiliates or Licensees or Sublicensees for resale, but Net Sales                shall                include the subsequent final sales to Third Parties by such Affiliates                or                Licensees or Sublicensees; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | Fair                Market Value shall be assigned to any and all non-cash consideration                such                as but not limited to any credit, barter, benefit, advantage or concession                received by Hana or its Affiliates or Licensees or Sublicensees in                payment                for sale of Product; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (g)   | as                used in this definition, a “sale” shall have occurred when Product are                billed out or invoiced; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------|

| (h)   | notwithstanding                anything herein to the contrary, the following shall not be considered                a                sale of Product under this                Agreement: |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | the                transfer of a Product to a Third Party without consideration to Hana                in                connection with the development or testing of a Product;                or |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | the                transfer of a Product to a Third Party without consideration in connection                with the marketing or promotion of the Product (e.g.,                samples). |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.70   | “**Non-Abandoning                Party**”                shall have the meaning set forth in Section                8.5.1. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.71   | “**Non-Competition                Terms**”                means the terms and conditions contained in Article 7 of the Transaction                Agreement between the Parties dated May 6,                2006. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.72   | “**Non-litigating                Party**”                shall have the meaning set forth in Section                9.2.5. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.73   | “**Notice                of Abandonment**”                shall have the meaning set forth in Section                8.5.1. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.74   | “**Party**”                means INEX or Hana and “**Parties**”                means INEX and Hana. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------|

| 1.1.75   | “**Patents**”                means the Licensed Patents and the Assigned                Patents. |
|--------------------|--------------------------------------------------------------------------------------------------------------|

| 1.1.76   | “**Person**”                means and includes any individual, corporation, partnership, firm,                joint                venture, syndicate, association, trust, government body, and any                other                form of entity or organization. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.77   | “**Pharmacovigilance**”                means all the activities associated with maintaining an effective                drug                safety monitoring system and adverse events reporting system in compliance                with the requirements of Regulatory                Authorities. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.78   | “**Prime                Rate**”                means the prime or equivalent rate quoted by the Bank of Canada from                time                to time. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.79   | “**Product**”                means any one or more of Sphingosomal Vincristine, Sphingosomal                Vinorelbine, and Sphingosomal                Topotecan. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.80   | “**Publishing                Party**”                shall have the meaning set forth in Section                10.4.1. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.1.81   | “**QA**”                means Quality Assurance, being that part of each management system,                within                Hana and INEX separately, having responsibility for assuring the                quality                of Material and Manufacturing in respect of compliance with Regulatory                Requirements. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.82   | “**QC**”                means Quality Control, being that part of each management system,                within                Hana and INEX separately, having responsibility for quality control                testing of Material in respect of compliance with Regulatory                Requirements. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.83   | “**Registrational                Clinical Trial**”                means any one of a Phase III clinical trial or pivotal Phase II clinical                trial conducted in furtherance of Regulatory                Approvals. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.84   | “**Regulatory                Activity**”                and “**Regulatory                Activities**”                mean any one or more of the regulatory activities to be performed                by Hana,                its Licensees, Sublicensees, or their respective Representatives                in                pursuit of the Development of each Product, including writing,                translation, compilation, notification, submission, filing, defense,                maintenance and renewal of Regulatory Approvals and payment of fees                associated therewith, and meeting with Regulatory                Authorities. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.85   | “**Regulatory                Approvals**”                means all necessary and appropriate regulatory approvals which must                be                obtained before placing each Product on the market in any country                in the                Territory in which such approval is required, including without                limitation, INDs, NDAs, and any other comparable terms as applicable                with                regard to any such approvals in any other country in the                Territory. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.86   | “**Regulatory                Authorities**”                means the FDA and any other like governmental authorities, whether                federal, provincial, state or municipal, regulating the manufacture,                importation, distribution, marketing, clinical testing and/or sale                of                therapeutic substances in the                Territory. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.87   | “**Regulatory                Requirements”**means                Applicable Laws and all rules, regulations and guidances in respect                of QC                and QA procedures and processes, manufacturing and production batch                records (including the master production record), packaging, handling,                storage, delivery and retention of raw material and finished product                samples and associated support data, and all licenses, certificates,                authorizations or requirements from Regulatory Authorities in the                Territory, including but not limited to cGMP Requirements in respect                of                the Manufacture of Material. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.88   | “**Regulatory                Submission**”                means any submission or filing made in furtherance of obtaining and                maintaining any Regulatory                Approvals. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.89   | “**Representatives**”                means, in respect of a Person, that Person’s Affiliates and their                respective directors, officers, employees, consultants, subcontractors,                licensees or sublicensees (including Licensees and Sublicensees)                as the                case may be, agents, representatives and other persons acting under                their                authority. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.90   | “**Royalty-free                License**”                means a license granted by Hana to INEX for any and all uses of the                MD                Anderson Patents outside the Hana Field in respect of which:  |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (a)   | subject                to Section 1.1.90(b), a fully paid up, royalty-free license;                and |
|-----------------|--------------------------------------------------------------------------------------------------------|

| (b)   | INEX                unconditionally, absolutely and irrevocably agrees with Hana to continue                to remain liable for royalty payments to MD Anderson under the MD                Anderson                License in respect of INEX’s use of the MD Anderson Patents outside the                Hana Field. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.91   | “**Sarris                Patents**”                means: |
|--------------------|-----------------------------------------------------------------------|

| (a)   | the                Sarris patents and patent applications jointly owned by MD Anderson                and                INEX, as set forth in **Exhibit                1.1.91**;                and |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | any                and all counterparts of the foregoing, including all divisionals,                provisionals, non-provisionals, and continuations, and all patents                issuing                on any of the foregoing and any foreign counterparts thereof, together                with all registrations, reissues, re-examinations, supplemental protection                certificates, additions, renewals or extensions thereof and any foreign                counterparts thereof; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | MD                Anderson (including annual fees and royalty rights to MD Anderson)                under                the terms and conditions of the MD Anderson License;                and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | INEX                (including milestone, Licensing/Sublicensing Revenue and royalty                rights)                under the terms and conditions of this                Agreement. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.92   | “**Service                Agreement**”                means the Service Agreement entered into between INEX and Hana dated                May                3, 2006 and effective as of April 3,                2006. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.93   | “**Sphingosomal                Topotecan**”                means a liposome that includes sphingomyelin and cholesterol and                contains                encapsulated topotecan, wherein the sphingomyelin comprises less                than 20%                dihydrosphingomyelin. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.94   | “**Sphingosomal                Topotecan R&D Expenses**”                shall have the meaning set forth in Section                3.3.4. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.95   | “**Sphingosomal                Vincristine**”                means a liposome that includes sphingomyelin and cholesterol and                contains                encapsulated vincristine, wherein the sphingomyelin comprises less                than                20% dihydrosphingomyelin. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.96   | “**Sphingosomal                Vincristine NDA**”                shall have the meaning set forth in Section                3.1.1. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.97   | **“Sphingosomal                Vincristine R&D Expenses”**shall                have the meaning set forth in Section                3.1.4 |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.98   | “**Sphingosomal                Vinorelbine**”                means a liposome that includes sphingomyelin and cholesterol and                contains                encapsulated vinorelbine, wherein the sphingomyelin comprises less                than                20% dihydrosphingomyelin. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.99   | **“Sphingosomal                Vinorelbine R&D Expenses”**shall                have the meaning set forth in Section                3.2.4. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.100   | “**Sublicense**”                means an agreement between: |
|---------------------|-------------------------------------------------------------------------|

| (a)   | a                Licensee and a Person to whom such Licensee has granted a sublicense                of                the rights granted under the License;                and |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (b)   | an                agreement between Hana and its Affiliate or between Hana and a Third                Party, to whom Hana has granted a sublicense of the rights granted                by INEX                to Hana in respect of one or more of the                following: |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | the                Licensed Patents; and |
|-----------------|------------------------------------------|

| (ii)   | that                portion of the Technology that relates to the Licensed                Patents. |
|------------------|----------------------------------------------------------------------------------------------------|

| 1.1.101   | “**Sublicensee**”                means a Person to whom a Licensee has granted a Sublicense and a                Person to                whom Hana has granted a Sublicense. Without limiting the generality                of the                foregoing, a Sublicensee shall be deemed to include any Person who                is                granted a Sublicense hereunder pursuant to the terms of the outcome                or                settlement of any infringement or threatened infringement or threatened                infringement action. |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.102   | “**Technical                Transfer**”                means the transfer by INEX and/or INEX’s Third Party contractors to Hana,                Hana’s Third Party contractors and/or INEX’s Third Party contractors of                those aspects of the Technology necessary and useful for the Manufacture                of Material, and includes Method                Transfer. |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.103   | “**Technology**”                includes: |
|---------------------|-------------------------------------------------------|

| (a)   | all                technical information and know-how relating to the technology claimed                in                the Patents in the Hana Field, including without limitation all such                information as is described in certain of the laboratory notebooks                enumerated in **Exhibit                1.1.103**attached                hereto; and |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | all                Confidential Information possessed by INEX on the Effective Date                of the                Definitive Agreements pertaining to the Products in the Hana Field                in                data, drawings, formulae, know-how, unpatented inventions, manufacturing                information, specifications, product design histories, technical                dossiers,                regulatory records, quality system documentation, whether protectable                or                not as trade secrets or otherwise including, without limitation,                standard                operating procedures, technical reports, synthetic protocols,                manufacturing protocols, animal protocols, invention disclosures,                manufacturing records, process development data, formulation records,                biological, chemical, pharmacological, toxicological assay results,                controls, clinical testing data, IND data and histology                slides. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.104   | “**Term**”                shall have the meaning set forth in Section                14.1. |
|---------------------|--------------------------------------------------------------------------------------------------------|

| 1.1.105   | “**Territory**”                means all of the countries and territories of the                world. |
|---------------------|--------------------------------------------------------------------------------------------------------------------|

| 1.1.106   | “**Third                Party(ies)**”                means any Person(s) other than INEX or Hana or any of their respective                Affiliates. |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.107   | “**Thomas                Patents**”                means |
|---------------------|----------------------------------------------------------------------|

| (a)   | the                Thomas patent applications owned by INEX as set forth in **Exhibit                1.1.9**                attached hereto; and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (b)   | any                and all counterparts of the foregoing, including all divisionals,                provisionals, non-provisionals, and continuations, and all patents                issuing                on any of the foregoing and any foreign counterparts thereof, together                with all registrations, reissues, re-examinations, supplemental protection                certificates, additions, renewals or extensions thereof and any foreign                counterparts thereof; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | MD                Anderson (including annual fees and royalty rights) under the terms                and                conditions of the MD Anderson License;                and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | INEX                (including milestone, Licensing/Sublicensing Revenue and royalty                rights)                under the terms and conditions of this                Agreement. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.108   | “**Transaction                Agreement**”                means the Transaction Agreement dated May 6, 2006 between Hana and                INEX. |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.109   | “**US                GAAP**”                means generally accepted accounting principles applied in the United                States of America. |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.110   | “**Valid                Claim**”                means either: |
|---------------------|---------------------------------------------------------------------------|

| (a)   | a                claim of an issued and unexpired patent which has not been held                unenforceable, unpatentable or invalid by a court or other governmental                agency of competent jurisdiction, and which has not been admitted                to be                invalid or unenforceable through reissue, disclaimer or otherwise;                or |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | a                claim in a patent application, provided that if such pending claim                has not                issued as a claim of an issued patent within seven (7) years after                the                filing date of such patent application, such pending claim shall                not be a                Valid Claim for purposes of this                Agreement. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**1.2  **
**Other        Definitions**

**Article      2**
**P**
**ATENT      AND TECHNOLOGY**

**2.1  **
**Amendment        of License Agreement**

| 2.1.1   | Subject                to the terms and conditions of this Agreement, the Parties hereby                agree: |
|-------------------|----------------------------------------------------------------------------------------------------------------|

| (a)   | to                terminate: |
|-----------------|------------------------------|

----

| (i)   | the                exclusive license by INEX to Hana under the MD Anderson Patents,                subject                to the terms and conditions set forth in the MD Anderson License,                to make,                have made, use, sell, offer for sale, import, and have imported Products                in the Hana Field within the Territory;                and |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | the                exclusive license by Hana to INEX under the Hana Intellectual Property,                subject to the terms and conditions of the License Agreement, to                make,                have made, use, sell, offer for sale, import, and have imported products                outside the Hana Field; and |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | to                affirm INEX’s grant to Hana, and Hana’s acceptance,                of: |
|-----------------|------------------------------------------------------------------------------------------------------|

| (i)   | an                exclusive license under the Licensed Patents to make, have made,                use,                sell, offer for sale, import, and have imported Products in the Hana                Field                within the Territory; and |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | an                exclusive license to the Technology to make, have made, use, sell,                offer                for sale, import, and have imported Products in the Hana Field within                the                Territory; and |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | to                the irrevocable and absolute grant, sale, assignment and conveyance                by                INEX to Hana, and Hana’s acceptance                of: |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | INEX’s                entire right, title and interest in and to the Thomas Patents subject                to                the terms and conditions set forth in the MD Anderson License;                and |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | INEX’s                entire right, title and interest in and to INEX’s joint ownership of the                Sarris Patents subject to the terms and conditions set forth in the                MD                Anderson License; |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.1.2   | It                is understood and agreed that the foregoing exclusive licenses in                Section                2.2.1(b)                grant to Hana the rights enumerated to the exclusion of all other                parties,                including INEX and its Affiliates. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.1.3   | It                is also understood that INEX retains exclusive rights under the Licensed                Patents and Technology outside the Hana                Field. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**2.2  **
**License**
**        Grant to**
** **
**INEX**

| 2.2.1   | Subject                to the terms and conditions of this Agreement, Hana hereby grants                to INEX                and INEX hereby accepts an, irrevocable world-wide, exclusive,                Royalty-Free License under the MD Anderson Patents to make, have                made,                use, sell, offer for sale, import, and have imported products outside                the                Hana Field subject only to the provisions of Sections 8.5 (relating                to                abandonment, withdrawal or discontinuance of patent protection) and                14.3                (relating to termination on                bankruptcy). |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.2.2   | In                respect of the license granted by Hana to INEX under Section 2.2.1,                the                Parties understand and agree that: |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (a)   | except                as otherwise provided in the MD Anderson License, the foregoing exclusive                licenses grant to INEX the rights enumerated to the exclusion of                all other                parties, including Hana and its Affiliates;                and |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Hana                retains exclusive rights under the Assigned Patents in the Hana                Field. |
|-----------------|-----------------------------------------------------------------------------------------------------------|

| 2.2.3   | Hana                hereby grants to INEX a non-exclusive license under the Patents and                Technology to make, have made, use, import and have imported Products                solely for non-commercial research, scholarly publication, education,                or                other non-commercial purposes. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.2.4   | Hana                hereby grants to INEX a non-exclusive license under the Patents and                Technology to carry out INEX’s activities under the Development Plan and                Services Agreement. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.2.5   | Hana                hereby grants to INEX a worldwide, royalty-free, non-exclusive license                under the Hana Intellectual Property to make, have made, use, sell,                offer                to sell, import, and have imported liposomes and liposomes having                an                active agent encapsulated, intercalated or entrapped therein outside                the                Hana Field, with the proviso that this grant does not extend                to: |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | any                Intellectual Property Rights licensed by Hana prior to the Effective                Date                of the Definitive Agreements, except to the extent that such license                permits Hana to grant such rights to INEX;                or |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | any                Hana Intellectual Property directed to the active agent                itself. |
|-----------------|---------------------------------------------------------------------------------------------------|

**2.3  **
**Compliance        with Third Party Agreements**

| 2.3.1   | Subject                to INEX’s performance of its obligations under this Agreement, and in                consideration for INEX’s sublicense of the BCCA Patents, Hana                unconditionally, absolutely and irrevocably covenants and agrees                with INEX                as primary obligor, to adopt as Hana’s own obligations every obligation of                INEX contained or set forth in the BCCA Agreements. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.3.2   | Subject                to Hana’s performance of its obligations under this Agreement, INEX                unconditionally, absolutely and irrevocably covenants and agrees                with Hana                to: |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | adopt                as INEX’s own obligations, the royalty obligations set forth in the MD                Anderson License to the extent such obligations arise from INEX’s, its                licensees’ or sublicensees’ use of the MD Anderson Patents outside the                Hana Field; and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | to                continue to comply with INEX’s royalty obligations set forth in the BCCA                Agreements to the extent such obligations arise from INEX’s, its                licensees’ or sublicensees’ use of the BCCA Patents outside the Hana                Field. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**2.4  **
**Licensing        and Sublicensing**

| 2.4.1   | With                respect to the licenses and assignments granted to Hana under Section                2.1,                subject to the terms and conditions set out in the BCCA Agreements                and the                MD Anderson License and Hana’s assumption of any and all license fees,                annual fees, milestone payments and royalty obligations set forth                in this                Agreement, Hana shall have the right to grant Licenses and Sublicenses                to                its Affiliates and to Third                Parties. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 2.4.2   | All                Licenses and Sublicenses granted under this Section 2.4 shall be                subject                to the following: |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | Hana                will cause each Affiliate so licensed or sublicensed to perform the                terms                of this Agreement as if such Affiliate were Hana                hereunder; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | each                Affiliate so licensed or sublicensed shall unconditionally, absolutely                and                irrevocably covenant and agree with INEX as primary obligor, to adopt                as                its own obligations every obligation of Hana contained or set forth                in                this Agreement to the extent pertinent to the scope of such License                or                Sublicense; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | Hana                unconditionally guarantees the performance of each Affiliate hereunder                as                if they were signatories to this Agreement to the extent the performance                or lack of performance is a breach of this                Agreement; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | the                obligations and liabilities of each Affiliate and Hana under this                Agreement shall be joint and several and INEX shall not be obliged                to seek                recourse against an Affiliate before enforcing its rights against                Hana.                For greater certainty it is hereby confirmed that any default or                breach by                an Affiliate of any term of this Agreement will also constitute a                default                by Hana under this Agreement, and INEX shall be entitled to exercise                its                rights hereunder, in addition to any other rights and remedies to                which                INEX may be entitled; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | each                License and Sublicense shall contain covenants by the Third Party                Licensee                and Sublicensee, as the case may be, for the benefit of INEX to observe                and perform similar terms and conditions to those in this                Agreement; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | all                Licenses and Sublicenses granted by Hana shall be further sublicensable                or                assignable without the prior written consent of INEX; provided however,                that Hana shall not license or sublicense any rights granted herein                to any                Person that in whole or in part, either alone or in partnership,                in                collaboration or in conjunction with any Person other than INEX,                whether                as principal, agent, employee, director, officer, shareholder, licensor                or                in any capacity or manner whatsoever, whether directly or indirectly                manufactures liposomal products without first either: (i) obtaining                INEX’s                written consent; or (ii) including in such License or Sublicense,                as the                case may be, a provision requiring the Licensee or Sublicense, as                the case                may be, to agree that it will not use the Technology for any purpose                other                than the Products; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (g)   | in                the event that Hana becomes aware of a material breach of any such                License                or Sublicense by a Third Party Licensee or Sublicensee, Hana shall                promptly notify INEX of the particulars of same and take all reasonable                steps to enforce the terms of such License or Sublicense, as the                case may                be; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (h)   | within                ten (10) Business Days after execution of each License or Sublicense,                as                the case may be, Hana shall provide INEX with a copy thereof, provided,                however, that only if Hana is bound by by the terms of an agreement                which                predates this Agreement and prohibits Hana from disclosing the financial                terms of each License or Sublicense, then Hana shall be permitted                to                redact the financial terms thereof.                The terms of each Sublicense Agreement shall be deemed to constitute                “Confidential Information” of Hana for all purposes of this Agreement, and                INEX shall not disclose the information contained in such Sublicense                Agreement to any Third Party except as authorized pursuant to Article                10                of                this Agreement; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (i)   | all                Licenses and Sublicenses shall terminate upon the termination of                Hana’s                rights granted herein unless events of default are cured by Hana                or its                Licensee or Sublicensee, as the case may be, within the period for                the                cure of default after notification by INEX as provided by the terms                of                this Agreement; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (j)   | any                Licensee who wishes to grant Sublicense or any Sublicensee who wishes                to                grant a further sub-Sublicense shall comply with the terms of this                Section                as if the further Sublicense or sub-Sublicense, as the case may be,                were a                License or Sublicense hereunder, including providing to INEX and                Hana the                information described in this Section, and obtaining the consent                referred                to in this Section, prior to any execution of any such Sublicense                or                sub-Sublicense; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (k)   | all                Licenses and Sublicenses shall include an obligation for each Licensee                and                Sublicensee to account for and report its sales of Product on the                same                basis as if such sales were sales of Hana, and INEX shall receive                compensation in the same amounts as if the sales of Product by the                Licensee or Sublicensee, as the case may be, were sales of Hana;                and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (l)   | Hana                shall remain responsible to INEX for the compliance of each Licensee                and                Sublicensee with the financial and other obligations due under this                Agreement. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.4.3   | With                respect to the licenses granted to INEX under Section 2.2, INEX shall                have                the right to grant licenses and sublicenses to its Affiliates and                to Third                Parties. All licenses and sublicenses will be consistent with the                terms of                this Agreement, shall not relieve Hana or INEX of their obligations                hereunder, and shall incorporate terms and conditions for each of                INEX’s                and Hana’s benefit comparable to those set forth in Section 2.4.2                applicable to Licenses and Sublicenses granted by                Hana. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**2.5**
**Payment      of Taxes**

**Article      3**
**LICENSE      FEES, MILESTONES AND ROYALTIES**

**3.1  **
**Sphingosomal        Vincristine.**

| 3.1.1   | Milestone                Payments: |
|-------------------|------------------------------------|

----

| (a)   | [***]                Dollars ($[***]) within ten (10) days following the FDA’s acceptance for                review of an NDA submission by Hana relating to Sphingosomal Vincristine                (the “**Sphingosomal                Vincristine NDA**”),                which payment shall be satisfied by Hana issuing to INEX a number                of                additional shares of Common Stock determined by dividing [***] Dollars                ($[***]) by the FMV as of the Sphingosomal Vincristine NDA filing                date;                provided however, if a Regulatory Submission equivalent to an NDA                is                accepted in any of the Designated EU States before the Sphingosomal                Vincristine NDA is accepted, then [***] (***) the milestone payment                due                under this Section 3.1.1(a) will be paid by Hana to INEX immediately                upon                the acceptance of that equivalent filing in any of the Designated                EU                States, and the remaining balance will be paid by Hana to INEX immediately                upon the acceptance of the Sphingosomal Vincristine NDA                by                the FDA; and |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | [***]                Dollars ($[***]) within ten (10) days following Hana’s receipt of the                approval by the FDA of the Sphingosomal Vincristine NDA, which payment                shall be made by Hana issuing to INEX a number of additional shares                of                Common Stock determined by dividing [***] Dollars ($[***]) by the                FMV as                of the date of such approval; provided however, if a Regulatory Submission                equivalent to an NDA is approved in any of the Designated EU States                before                the Sphingosomal Vincristine NDA is approved by the FDA, [***] (***)                the                milestone payment due under this Section                3.1.1(b) will be paid by Hana to INEX immediately upon the approval                of                that equivalent filing in any of the Designated EU States, and the                remaining balance will be paid by Hana to INEX immediately upon the                approval of the Sphingosomal Vincristine NDA by the                FDA. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | For                the avoidance of doubt, each of the milestone payments described                in                subparagraphs (a) and (b) of this Section 3.1.1 above represent one-time                payments to INEX, and shall be due only upon the first occurrence                of the                events described in each such subparagraph. For example, the milestone                payment described in subparagraph (a) above will be due only once,                following the FDA’s acceptance for review of the Sphingosomal Vincristine                NDA. No additional milestone payments to INEX shall be due from Hana                pursuant to subparagraph (a) in connection with any subsequent NDA                submission by Hana relating to Sphingosomal                Vincristine. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | With                respect to Net Sales of Sphingosomal Vincristine in the United States,                a                royalty equal to the sum of: (i) [***] percent ([***]%) of Net Sales                in                consideration of Patents if the Product sold is embraced within any                Valid                Claim under the Patents in the United States; (ii) [***] percent                ([***]%)                of Net Sales in consideration of, and during any period of Product                exclusivity provided by the laws of the United States of America,                including but not limited to marketing exclusivity in the form of                data                exclusivity, pediatric exclusivity, and orphan drug designation                exclusivity; and (iii) [***] percent ([***]) of Net Sales in consideration                of Technology; provided, however, that the total royalty paid shall                be                limited to [***] percent ([***]%) of cumulative Net Sales up to [***]                Dollars ($[***]), and limited to [***] percent ([***]) of cumulative                Net                Sales exceeding [***] Dollars ($[***]); and |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (b)   | With                respect to Net Sales of Sphingosomal Vincristine in each country                of the                Territory other than the United States, a royalty of [***] percent                ([***]%) of Net Sales in consideration of Patents and Technology;                provided, however, that the total royalty paid shall be limited to                [***]                percent ([***]%) of cumulative Net Sales up to [***] Dollars ($[***]),                and                increased to [***] percent ([***]%) of cumulative Net Sales in excess                of                [***] Dollars ($[***]). |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Approved      Sphingosomal Vincristine Equivalents**

**Sphingosomal      Vincristine R&D Expenses**

| (a)   | [***]                Dollars ($[***]); or |
|-----------------|-------------------------------------------|

| (b)   | [***]                Dollars ($[***]) per patient treated in a Registrational Clinical                Trial; |
|-----------------|--------------------------------------------------------------------------------------------------------------|

**3.2  **
**Sphingosomal        Vinorelbine**

| (a)   | One                Million Dollars ($1,000,000) upon on the date the first patient is                enrolled in any clinical trial of Sphingosomal Vinorelbine conducted                pursuant to an IND sponsored by Hana, of which INEX acknowledges Five                Hundred Thousand Dollars ($500,000) has been paid by wire transfer to                INEX of immediately available funds and the remaining Five Hundred                Thousand Dollars ($500,000) has been paid by Hana issuing to INEX a                number of additional shares of Common Stock determined by                dividing Five Hundred Thousand Dollars ($500,000) by the FMV as                of the date of such first patient                enrollment; |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (b)   | [***]                Dollars ($[***]) upon the date the first patient is enrolled in a                Phase II                clinical trial of Sphingosomal Vinorelbine conducted pursuant to                an IND                sponsored by Hana, which payment shall be made by Hana issuing to                INEX a                number of additional shares of Common Stock determined by dividing                [***]                Dollars ($[***]) by the FMV as of the date of such first patient                enrollment; and |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | [***]                ($[***]) upon the approval by the FDA of an NDA relating to Sphingosomal                Vinorelbine, which payment shall be made by Hana issuing to INEX                a number                of additional shares of Common Stock determined by dividing [***]                Dollars                ($[***]) by the FMV as of the date of such FDA approval; provided                however,                if a Regulatory Submission equivalent to an NDA is approved in any                of the                Designated EU States before an NDA relating to Sphingosomal Vinorelbine                is                approved by the FDA, [***] the milestone due under this Section 3.2.1(c)                will be paid by Hana to INEX immediately upon approval of that equivalent                filing and the remaining balance will be paid by Hana to INEX immediately                upon the approval of an NDA relating to Sphingosomal Vinorelbine                by the                FDA. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | For                the avoidance of doubt, each of the milestone payments described                in                subparagraphs (a), (b) and (c) of this Section 3.2.1 above represent                one-time payments to INEX, and shall be due only upon the first occurrence                of the events described in each such subparagraph. For example, the                milestone payment described in subparagraph (a) above will be due                only                once, upon the date the first patient is enrolled in a clinical trial                of                Sphingosomal Vinorelbine conducted pursuant to an IND sponsored by                Hana.                No additional milestone payments to INEX shall be due from Hana pursuant                to subparagraph (a) in connection with any subsequent clinical trials                sponsored by Hana. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | With                respect to Net Sales of Liposomal Vinorelbine in the United States,                a                royalty equal to the sum of: (i) [***] percent ([***]%) of Net Sales                in                consideration of Patents if the Product sold is embraced within any                Valid                Claim under the Patents in the United States; (ii) [***] percent                ([***]%)                of Net Sales in consideration of, and during any period of Product                exclusivity provided by the laws of the United States of America,                including but not limited to marketing exclusivity in the form of                data                exclusivity, pediatric exclusivity, and orphan drug designation                exclusivity; and (iii) [***] percent ([***]%) of Net Sales in                consideration of Technology; provided, however, that the total royalty                paid shall be limited to [***] percent ([***]%) of cumulative Net                Sales up                to [***] Dollars ($[***]), and limited to [***] percent ([***]%)                of                cumulative Net Sales in excess of [***] Dollars ([***]); and |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (b)   | With                respect to Net Sales of Sphingosomal Vinorelbine in each country                of the                Territory other than the United States, a royalty of [***]percent                ([***]%)                of Net Sales in consideration of Patents and Technology; provided,                however, that the total royalty paid shall be limited to [***] percent                ([***]%) of cumulative Net Sales up to [***] Dollars ($[***]), and                increased to [***] percent ([***]%) of cumulative Net Sales in excess                of                [***] Dollars ($[***]). |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | If,                during a given calendar year, there is sale of a generic Sphingosomal                Vinorelbine or sale of an approved equivalent to Sphingosomal Vinorelbine                (collectively, “**Approved                Sphingosomal Vinorelbine Equivalents**”)                in any country in the Territory, then, for such country, the total                amount                of royalties payable to INEX for the Net Sales of Sphingosomal Vinorelbine                in such country during such calendar year will be reduced to [***]                percent                ([***]%) of the royalties payable to INEX pursuant to Section 3.2.2                for                such calendar year, in such                country. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Sphingosomal      Vinorelbine R&D Expenses**

| (a)   | [***]                Dollars ($[***]); or |
|-----------------|-------------------------------------------|

| (b)   | [***]                Dollars ($[***]) per patient treated in a Registrational Clinical                Trial; |
|-----------------|--------------------------------------------------------------------------------------------------------------|

**3.3  **
**Sphingosomal        Topotecan**

| 3.3.1   | Milestone                Payments: |
|-------------------|------------------------------------|

| (a)   | [***]                Dollars ($[***]) upon the date the first patient is enrolled in any                clinical trial of Sphingosomal Topotecan conducted pursuant to an                IND                sponsored by Hana, which payment shall be made by Hana issuing to                INEX a                number of additional shares of Common Stock determined by dividing                [***]                Dollars ($[***]) by the FMV as of the date of such first patient                enrollment; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (b)   | [***]                Dollars ($[***]) upon the date the first patient is enrolled in a                Phase II                clinical trial of Sphingosomal Topotecan conducted pursuant to an                IND                sponsored by Hana, which payment shall be made by Hana issuing to                INEX a                number of additional shares of Common Stock determined by dividing                [***]                Dollars ($[***]) by the FMV as of the date of such first patient                enrollment; and |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | [***]                Dollars ($[***]) upon the approval by the FDA of an NDA relating                to                Sphingosomal Topotecan, which payment shall be made by Hana issuing                to                INEX a number of additional shares of Common Stock determined by                dividing                [***] Dollars ($[***]) by the FMV as the date of such FDA approval;                provided however, if a Regulatory Submission equivalent to an NDA                is                approved in any of the Designated EU States before an NDA relating                to                Sphingosomal Topotecan is approved by the FDA, [***] the milestone                due                under this Section 3.3.1(c) will be paid by Hana to INEX immediately                upon                approval of that equivalent filing and the remaining balance will                be paid                by Hana to INEX immediately upon the approval of an NDA relating                to                Sphingosomal Topotecan by the FDA. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | For                the avoidance of doubt, each of the milestone payments described                in                subparagraphs (a), (b) and (c) of this Section 3.3.1 above represent                one-time payments to INEX, and shall be due only upon the first occurrence                of the events described in each such subparagraph. For example, the                milestone payment described in subparagraph (a) above will be due only                once, upon the date the first patient is enrolled in a clinical trial                of                Sphingosomal Topotecan conducted pursuant to an IND sponsored by                Hana. No                additional milestone payments to INEX shall be due from Hana pursuant                to                subparagraph (a) in connection with any subsequent clinical trials                sponsored by Hana. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | With                respect to Net Sales of Sphingosomal Topotecan in the United States,                a                royalty equal to the sum of: (i) [***] percent ([***]%) of Net Sales                in                consideration of Patents if the Product sold is embraced within any                Valid                Claim under the Patents in the United States; (ii) [***] percent                ([***]%)                of Net Sales in consideration of, and during any period of Product                exclusivity provided by the laws of the United States of America,                including but not limited to marketing exclusivity in the form of                data                exclusivity, pediatric exclusivity, and orphan drug designation                exclusivity; and (iii) [***] percent ([***]%) of Net Sales in                consideration of Technology; provided, however, that the total royalty                paid shall be limited to [***] percent ([***]%) of cumulative Net                Sales up                to [***] Dollars ($[***]), and limited to [***] percent ([***]%)                of                cumulative Net Sales in excess of [***] Dollars ($[***]); and |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | With                respect to Net Sales of Sphingosomal Topotecan in each country of                the                Territory other than the United States, a royalty of [***] percent                ([***]%) of Net Sales in consideration of Patents and Technology;                provided, however, that the total royalty paid shall be limited to                [***]                percent ([***]%) of cumulative Net Sales up to [***] Dollars ($[***]),                and                increased to [***] percent ([***]%) of cumulative Net Sales in excess                of                [***] Dollars ($[***]). |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (a)   | If,                during a given calendar year, there is sale of a generic Sphingosomal                Topotecan or sale of an approved equivalent to Sphingosomal Topotecan                (collectively, “**Approved                Sphingosomal Topotecan Equivalents**”)                in any country in the Territory, then, for such country, the total                amount                of royalties payable to INEX for the Net Sales of Sphingosomal Topotecan                in such country during such calendar year will be reduced by [***]                percent                ([***]%) of the royalties payable to INEX pursuant to Section 3.3.2                for                such calendar year, in such                country. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Sphingosomal      Topotecan R&D Expenses**

| (a)   | [***]                Dollars ($[***]); or |
|-----------------|-------------------------------------------|

| (b)   | [***]                Dollars ($[***]) per patient treated in a Registrational Clinical                Trial; |
|-----------------|--------------------------------------------------------------------------------------------------------------|

**3.4  **
**Limitation        on Payment **
**Using        Common Stock**

**Maximum      Issuance Amount**

**3.5  **
**Assumption        of Milestone and Royalty Obligations**

| 3.5.1   | As                a condition of the grant of: |
|-------------------|------------------------------------------------|

| (a)   | licence                by INEX to Hana of the Licensed Patents and Technology;                and |
|-----------------|---------------------------------------------------------------------------------------------------|

----

| (b)   | assignment                by INEX to Hana of the Assigned Patents, |
|-----------------|--------------------------------------------------------------------|

| 3.5.2   | For                avoidance of doubt, the obligations of Hana under Section 3.5.1 are                in                addition to and not in substitution of any other obligations set                forth in                this Article 3. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**3.6  **
**Remuneration        Respecting Sublicensees**

| 3.6.1   | In                the event Hana licenses or sublicenses its rights under Sphingosomal                Vincristine before the FDA approves the Sphingosomal Vincristine                NDA or a                Designated EU State approves a Regulatory Submission that is equivalent                to                an NDA, INEX shall be entitled to receive [***] percent ([***]%)                of any                Licensing/Sublicensing Revenue payable to Hana by such Licensee or                Sublicensee. In the event Hana licenses or sublicenses its rights                to                Sphingosomal Vincristine after the FDA approves the Sphingosomal                Vincristine NDA or a Designated EU State approves a Regulatory Submission                that is equivalent to an NDA, INEX shall be entitled to receive [***]                percent ([***]%) of any Licensing/Sublicensing Revenue payable to                Hana by                such Licensee or Sublicensee. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.6.2   | In                the event Hana licenses or sublicenses its rights under Sphingosomal                Vinorelbine, INEX shall be entitled to share the Licensing/Sublicensing                Revenue payable to Hana, if any, as                follows: |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | INEX’s                share of such Licensing/Sublicensing Revenue shall be [***] percent                ([***]%) of any Licensing/Sublicensing Revenue payable to Hana by                such                Licensee or Sublicensee during the period commencing on the Effective                Date                of the Definitive Agreements and ending on the date immediately preceding                the date the first patient is enrolled in a Phase II clinical trial                of                Sphingosomal Vinorelbine; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | INEX’s                share of such Licensing/Sublicensing Revenue shall be reduced to                [***]                percent ([***]%) of any Licensing/Sublicensing Revenue payable to                Hana by                such Licensee or Sublicensee on or after the date the first patient                is                enrolled in a Phase II clinical trial of Sphingosomal Vinorelbine                and                ending on the date immediately preceding the earlier to occur                of: |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | the                date the first patient is enrolled in a Phase III clinical trial                of                Sphingosomal Vinorelbine; or |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | the                acceptance of the NDA or its equivalent Regulatory Submission for                Sphingosomal Vinorelbine; and |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------|

| (c)   | INEX’s                share of such Licensing/Sublicensing Revenue shall be reduced to                [***]                percent ([***]%) of any Licensing/Sublicensing Revenue payable to                Hana by                such Licensee or Sublicensee on or after the earlier to occur                of: |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | the                date the first patient is enrolled in a Phase III clinical trial                of                Sphingosomal Vinorelbine; or |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (ii)   | the                acceptance of the NDA or its equivalent Regulatory Submission for                Sphingosomal Vinorelbine. |
|------------------|-------------------------------------------------------------------------------------------------------------------------------|

| 3.6.3   | In                the event Hana licenses or sublicenses its rights under Sphingosomal                Topotecan, INEX shall be entitled to share the Licensing/Sublicensing                Revenue payable to Hana, if any, as                follows: |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | INEX’s                share of such Licensing/Sublicensing Revenue shall be [***] ([***]%)                of                any Licensing/Sublicensing Revenue payable to Hana by such Licensee                or                Sublicensee during the period commencing on the Effective Date of                the                Definitive Agreements and ending on the date immediately preceding                the                date the first patient is enrolled in a Phase II clinical trial of                Sphingosomal Topotecan; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | INEX’s                share of such Licensing/Sublicensing Revenue shall be reduced to                [***]                percent ([***]%) of any Licensing/Sublicensing Revenue payable to                Hana by                such Licensee or Sublicensee on or after the date the first patient                is                enrolled in a Phase II clinical trial of Sphingosomal Topotecan and                ending                on the date immediately preceding the earlier to occur                of: |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | the                date the first patient is enrolled in a Phase III clinical trial                of                Sphingosomal Topotecan, or |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | the                acceptance of the NDA or its equivalent Regulatory Submission for                Sphingosomal Topotecan. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------|

| 3.6.4   | Notwithstanding                anything to the contrary contained in this Section 3.6, Hana shall                have no                obligation to pay to INEX its respective share of any such                Licensing/Sublicensing Revenue unless and until Hana actually receives                such Licensing/Sublicensing Revenue from its Licensee or                Sublicensee. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.6.5   | Where                any Licensing/Sublicensing Revenue payable to, collected or received                by                Hana or its Affiliates is in Dollars, Hana shall pay to INEX, INEX’s share                of such Licensing/Sublicensing Revenue within ten (10) days of Hana                or its                Affiliate’s receipt of same. Where any Licensing/Sublicensing Revenue                payable to, collected or received by Hana or its Affiliates is derived                from a country other than the United States of America, INEX’s portion of                such Licensing/Sublicensing Revenue shall be converted to the equivalent                in Dollars on the same date that Hana converts such Licensing/Sublicensing                Revenue to Dollars, in which case the amount of Dollars pursuant                to an                actual conversion shall be included in the Licensing/Sublicensing                Revenue                and Hana shall pay to INEX, INEX’s share of such Licensing/Sublicensing                Revenue within ten (10) days of such conversion. If at any time the                Parties agree that it is not practical or possible for Hana to forthwith                convert Licensing/Sublicensing Revenue paid in foreign currency to                Dollars, or if legal restrictions prevent the conversion of part                or all of                the Licensing/Sublicensing Revenue to Dollars, Hana shall have the                right                and option, upon consultation with INEX, to deposit INEX’s share of such                Licensing/Sublicensing Revenue in local currency, in an account in                INEX’s                sole name in a bank or depository in the country where such                Licensing/Sublicensing Revenue is generated. Hana                shall make such deposit within ten (10) days of Hana or its Affiliate’s                receipt of said foreign currency. The last date of signature of any                duly                executed License or Sublicense between Hana and a Licensee or Sublicensee                shall be deemed to be the date upon which Licensing/Sublicensing                Revenue                is received by Hana for the purposes of determining the percentage                of                Licensing/Sublicensing Revenue payable to INEX pursuant to Sections                3.6.1,                3.6.2 and 3.6.3. Hana shall make Commercially Reasonable Efforts                to inform                INEX in a timely manner of material legislative and economic changes                in                such country in which such deposit was made so as to enable INEX                to more                readily access, convert and/or transfer from such country, INEX’s share of                Licensing/Sublicensing Revenue deposited in such country by                Hana. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 3.6.6   | Notwithstanding                Section 3.6.5, if any Licensing/Sublicensing Revenue other than cash                is                payable to, collected or received by Hana or its Affiliates, Hana                may                elect to pay to INEX, INEX’s share of Licensing/Sublicensing Revenue by                way of cash, common stock of Hana, common stock of another corporation                acceptable to INEX, or any combination thereof. If Hana elects to                pay INEX                using the Common Stock of Hana or the common stock of another corporation                acceptable to INEX, the following shall                apply: |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | the                last date of signature of any duly executed License or Sublicense                between                Hana and a Licensee or Sublicensee, as the case may be, shall be                deemed to                be the date upon which Licensing/Sublicensing Revenue is received                by Hana                for the purposes of determining the percentage of Licensing/Sublicensing                Revenue payable to INEX pursuant to Sections 3.6.1, 3.6.2 and                3.6.3; |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | the                value of the economic benefit of the Licensing/Sublicensing Revenue                established by a Third Party banker or valuator, measured in Dollars                and                applied to the percentage entitlement of INEX determined pursuant                to                Section 3.6.6(a), shall be the assessed value (the “**Assessed                Value**”)                to be used in determining the number of shares of Common Stock of                Hana or                common stock of another corporation acceptable to INEX payable to                INEX                pursuant to Section 3.6.6(c); and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | Hana                will pay INEX using Common Stock of Hana or common stock of another                corporation acceptable to INEX as                follows: |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | the                Parties will mutually agree on the par value per share of common                stock of                Hana or of another corporation acceptable to INEX;                and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | Hana                will issue or assign to INEX as applicable, a number of shares of                Common                Stock of Hana or common stock of another corporation acceptable to                INEX by                dividing the Assessed Value by the FMV as of the date upon which                Licensing/Sublicensing Revenue was deemed to have been received by                Hana                pursuant to Section 3.6.6(a). |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.6.7   | If                Hana elects to pay Licensing/Sublicensing Revenue using a combination                of                cash and stock as described in this Section, the Assessed Value used                to                calculate the stock payable shall be reduced by the value of Dollars                actually paid to INEX in accordance with Section                3.6.5. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | Hana’s                payment of Licensing/Sublicensing Revenue in the form of stock pursuant                to                his Section shall be made within ten (10) days of Hana’s receipt of                same. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.6.8   | Hana’s                payment of Licensing/Sublicensing Revenue under this Section 3.6                shall be                accompanied by an accounting setting out all Licensing/Sublicensing                Revenue payable to, collected or received by Hana or its Affiliates,                segmented according to Product, Licensee and Sublicensee identified                by                name, and the last date on which each License and Sublicense was                executed. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**3.7  **
**Third        Party Payments**

| 3.7.1   | If,                during the term of this Agreement:  |
|-------------------|-------------------------------------------------------------|

| (a)   | Hana                and INEX mutually agree that it is necessary to seek a license from                any                Third Party in the Territory in order to avoid infringement during                the                exercise of the rights herein granted; or |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | if                as a result of any complaint alleging infringement or violation of                any                patent or other Intellectual Property Rights is made against Hana,                its                Affiliate or its Licensee or Sublicensee with respect of the Manufacture,                use or sale of a Product in the Hana Field, where such Manufacture,                use or                sale is encompassed by one or more Patents or Technology, and a                settlement, consent judgment or award of Damages determined by a                court of                competent jurisdiction requires Hana to make payment of Damages to                a Third                Party in satisfaction of such complaint;                or |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | if                an independent, mutually acceptable Third Party patent attorney determines                that such a license is required (in accordance with the procedure                outlined                in this Section 3.7.1); |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Offset      Amount**
**Punitive      Amount**

| 3.7.2   | Notwithstanding                the provisions of Section 3.7.1, if the license from the Third Party                or                the royalty or other amount payable to such Third Party gives rise                to an                indemnification obligation under one or more of the Definitive Agreements                in favor of Hana on the part of INEX, then such royalty or other                amount                shall be paid by INEX as Damages in accordance therewith; provided,                however, that Hana agrees to use all reasonable efforts to avoid                a finding                of willful infringement of such Third Party’s                rights. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**3.8  **
**Compulsory        Licenses**

| 3.8.1   | avail                itself of the royalty reduction set out in Sections 3.1.3, 3.2.3,                or                3.3.3, if applicable; or |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 3.8.2   | have                the benefit in such country of the same terms granted to such Third                Party                to the extent that such terms taken as a whole are more favorable                than                those of this Agreement. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**3.9  **
**Reports        and Payment**

| 3.9.1   | all                Net Sales segmented in each such report according to sales by Hana,                each                Affiliate and each Licensee and Sublicensee, as well as on a                country-by-country basis, and month-by-month                basis; |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.9.2   | deductions                from gross revenues by the categories for same set out in the definition                of Net Sales; and |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------|

| 3.9.3   | the                rates of exchange used to convert such royalties to Dollars from                the                currency in which such sales were made. For the purposes hereof,                such                conversion calculations are to be made on a monthly basis and the                rates of                exchange to be used for converting royalties hereunder to Dollars                shall be                those in effect for the purchase of Dollars as certified by the noon                buying rate of the Federal Reserve Bank of New York on the first                Business                Day of the quarter with respect to which the payment is                due. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**3.10  **
**Withholding        Taxes**

| 3.10.1   | Hana                shall be deemed to be the sole payer of payments owed to INEX under                this                Agreement and shall not have the right to substitute any domestic                or                foreign Affiliate for that purpose,                and |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.10.2   | in                the event that Hana takes any action, including, without limitation,                the                assignment of this Agreement, any licensing or sublicensing permitted                hereby, any change of jurisdiction of residence or any reorganization                or                change in its business or structure so that, after such action, the                withholding tax on the payments under this Agreement would be                substantially more than those in effect on the Effective Date of                the                Definitive Agreements, Hana shall                either: |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | with                the co-operation of INEX, arrange its affairs so that the withholding                tax                consequences to INEX are not materially worse than those in effect                prior                to such action; or |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (b)   | gross                up the payments otherwise owed to INEX so that INEX receives net                of                withholding taxes the amount INEX would have received but for such                action. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**3.11  **
**Foreign        Payments**

**3.12  **
**Method        of Payment**

**3.13  **
**Late        Payments**

| 3.13.1   | the                Prime Rate(s) during the period of late payment plus [***] percent                ([***]%) interest compounded monthly,                or |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.13.2   | the                maximum rate permitted by law; |
|--------------------|---------------------------------------------------|

**3.14  **
**Records**

**3.15  **
**Audits**

----

**Article      4**
**DEVELOPMENT      OBLIGATIONS**

**4.1  **
**Development        Plans**

| 4.1.1   | The                Parties acknowledge having executed a detailed Development Plan for                the                Development of each Product, which describes the specific Clinical                Activities, Regulatory Activities, Technical Transfer activities,                and                Manufacturing activities to be performed in the Territory for a twelve                (12) month period following the Effective Date of the Definitive                Agreements. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.1.2   | The                Development Plan will be reviewed from time to time as the Parties                reasonably determine to be necessary or                useful. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.1.3   | The                Development Plan shall be incorporated herein by reference and all                Development undertaken thereunder shall be conducted by Hana in compliance                with Regulatory Requirements. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**4.2  **
**Development        Efforts**

| 4.2.1   | Hana                shall use Commercially Reasonable Efforts to Develop each Product                in the                Territory (including carrying out its responsibilities under the                Development Plan) to: |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | conduct                or cause to be conducted the necessary and appropriate clinical trials                as                necessary to obtain and maintain Regulatory Approvals for each Product;                and |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | prepare,                file and prosecute or cause to be prepared, filed and prosecuted                the                Regulatory Submission for each                Product. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.2.2   | Hana                will provide INEX with written reports to keep INEX fully informed                of the                progress of the Development of each Product as                follows: |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | at                the close of each Calendar Quarter during the first twenty-four (24)                months following the Effective Date of the Definitive Agreements;                and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | on                or before June 31 and December 31 of each and every calendar year                thereafter. |
|-----------------|----------------------------------------------------------------------------------------------------------------|

**4.3  **
**Transition        Committees**

**4.4  **
**Subcontractors**

----

**Article      5**
**COMMERCIALIZATION      OBLIGATIONS**

**5.1  **
**Regulatory        Compliance**

| **5.2  ** | **Marqibo                Trade-mark** |
|---------------------|---------------------------------------|

| 5.2.1   | The                Parties acknowledge that INEX has taken all necessary, and has                caused                its wholly owned Affiliate                to                take all steps necessary to                assign to Hana all applications for trade-mark and all registered                trade-marks for Marqibo in all jurisdictions within the Territory. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.2.2   | Except                as provided herein, Hana at its sole cost and expense, shall be                responsible for the selection, registration and maintenance of all                other                trademarks which it employs in connection with each Product in the                Territory and shall own and control such trademarks during the term                of                this Agreement and following its termination or                expiration. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **5.3  ** | **Labeling                and Patent Marking** |
|---------------------|------------------------------------------------|

| **5.4  ** | **Commercialization                Efforts** |
|---------------------|----------------------------------------------|

| **5.5  ** | **Consequence                of No Sales** |
|---------------------|--------------------------------------------|

| 5.5.1   | In                addition to the terms of Section 5.4, Hana shall be deemed to have                breached its obligation to use Commercially Reasonable Efforts in                conducting marketing of a Product in any country in the Major Markets                if,                for a continuous period of one hundred and eighty (180) days at any                time                following launch of commercial sales of the Product in any such country                in                the Major Markets, no sales of the Product are made in the ordinary                course                of business in such country by Hana, an Affiliate, a Licensee or                a                Sublicensee, unless: |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | The                Parties mutually agree it is to their mutual benefit to delay commercial                sales of Product in such country;                or |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Hana                is prevented, restricted, interfered with or delayed in making such                sales                by reason of a cause beyond Hana’s reasonable control and can demonstrate                same to INEX; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.5.2   | If                Hana breaches its obligation set forth in Section                5.5.1: |
|-------------------|-------------------------------------------------------------------------------------------|

----

| (a)   | INEX                shall be entitled to terminate all rights granted to Hana in the                Definitive Agreements in respect of each such Product in such country                in                the Major Markets by written notice to Hana in the event that Hana                is in                default of its obligations under Section 5.5.1 and fails to remedy                such                default within sixty (60) days after notice thereof by INEX;  |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | All                Licenses and Sublicenses granted by Hana in respect of such Product                in                such country in the Major Markets shall forthwith terminate upon                the                effective date of termination in Section 5.5.2(a);                and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | Hana                shall continue to be bound by and shall comply with Sections 14.6,                14.8,                and any other Sections which are intended to survive any termination                of                rights under this Agreement. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**5.6  **
**Reports**

| 5.6.1   | Hana                shall deliver to INEX within thirty (30) days after the end of each                Calendar Quarter reports setting forth in general terms, reasonably                sufficient for evaluation of the diligence obligations contained                herein,                the efforts Hana has made to Commercialize the Product during the                year,                including any significant adverse developments, and any plans for                or                occurrences of any commercial sales of the Product in any jurisdiction                and                a summary of the efforts it intends to make in the upcoming year(s)                on                these matters.                Hana shall consider any INEX input and comments related to Hana’s plan for                the upcoming year(s), provided that it is understood that Hana shall                have                final decision making responsibility for such                plans. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.6.2   | To                the extent that such could not be appropriately communicated to INEX                in                accordance with Section 5.6.1, Hana shall keep INEX informed in a                timely                manner of significant developments in Hana’s (and its Affiliates’,                Licensees’ and Sublicensees’, as the case may be) progress of its efforts                to Commercialize the Product, including without limitation, any                significant adverse developments, and any plans for or occurrences                of any                commercial sales of the Product in any                jurisdiction. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      6**
** **
**PRODUCT      SAFETY AND REGULATORY COMPLIANCE**

**6.1  **
**Regulatory        Responsibilities**

| 6.1.1   | Hana                shall use its Commercially Reasonable Efforts to ensure that none                of its                Representatives who participate in any Development                activities: |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | is                or has been suspended, debarred or disqualified by the                FDA; |
|-----------------|----------------------------------------------------------------------------------------------|

| (b)   | has                been convicted of any offence that would form the basis for any                suspension, disqualification or debarment;                or |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | is                or has been subject to any proceedings for the suspension,                disqualification or debarment. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------|

----

| 6.1.2   | Upon                the re-activation and/or transfer by INEX to Hana of the NDA or IND,                as                the case may be, in respect of each Product, Hana shall be responsible                for                using Commercially Reasonable Efforts to maintain and fulfill all                Regulatory Requirements with respect to such Product that are imposed                upon                Hana as the holder of Regulatory Submissions and Regulatory                Approvals. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.1.3   | Hana                and/or its Representatives’ Manufacturing, shipping and distribution of                Material for clinical and commercial use shall be done in accordance                with                applicable specifications and Regulatory Requirements. Hana shall                maintain                and shall require its Representatives who receive, handle, store,                ship or                distribute Product to maintain a record retention policy consistent                with                cGMP and Regulatory Requirements, and to maintain records with sufficient                detail to facilitate traceability in the event of recalls or voluntary                withdrawals of Product. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.1.4   | In                respect of each Product, Hana will use Commercially Reasonable Efforts                to                make such changes as reasonably necessary to the master production                record,                specifications, procedures, processes, Materials, facilities, equipment                or                any matter utilized by Hana under this Agreement or contained or                reference                in documents submitted to Regulatory Authorities to meet new Regulatory                Requirements and guidelines in the                Territory. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**6.2  **
**Pharmacovigilance**

| 6.2.1   | Upon                the transfer, by INEX to Hana of the INDs for Sphingosomal Vinorelbine                and                Sphingosomal Topotecan, and the NDA for Sphingosomal Vincristine,                Hana                shall be responsible for, in respect of each such Product, performing                Pharmacovigilance in respect of all pre-Regulatory Approval Clinical                Activities and all post-Regulatory Approval Product safety monitoring                in                accordance with Regulatory Requirements, in addition to all other                Regulatory Activities for which Hana is                responsible. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.2.2   | For                as long as Material sourced, Manufactured or quality released by                INEX                remains available for use in approved clinical trials, Hana                shall: |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | inform                INEX within five (5) Business Days of any complaint received or regulatory                action taken in respect of such Material and shall seek INEX’s opinion                before passing judgment on the quality of such Material to any Third                Party; and |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | provide                INEX with a copy(ies) of all documentation provided to and received                from                Regulatory Authorities in respect of such complaint or Adverse Drug                Event,                within one (1) Business Day of sending or receiving                same. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**6.3  **
**Recalls        and Product Withdrawals**

| 6.3.1   | If                either Party is required or requested by any Regulatory Authority                to                recall or withdraw any Clinical Trial Material for any reason, or                should                either Party decide voluntarily to withdraw any Clinical Trial                Material: |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | the                Party in whose name the applicable IND file is registered will be                responsible for coordinating such recall or product                withdrawal; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Hana                shall pay the costs and expenses of such recall or product withdrawal,                subject to recovery of some or all of same in accordance with the                terms of                Section 6.3.2; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (c)   | Unless                INEX is liable for such costs and expenses in accordance with the                terms of                Section 6.3.2, Hana will remain responsible to INEX for payment of                all                services in respect of the Manufacture and supply of Material;                and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | Both                Parties will cooperate fully with one another in connection with                any such                recall or product withdrawal. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.3.2   | If                a recall or product withdrawal is due to INEX’s negligence, willful                misconduct or breach of this Agreement or of the Service Agreement,                INEX                will reimburse Hana for all of Hana’s reasonable costs and expenses                actually incurred by Hana in connection with the recall or product                withdrawal, including any Service fees and expenses associated with                the                supply of the Product recalled or withdrawn, costs of retrieving                Product                already delivered to customers, costs and expenses Hana is required                to pay                for notification, shipping and handling charges, destruction or return                of                the defective Product or otherwise and such other reasonable costs                as may                be reasonably related to the recall or product                withdrawal. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.3.3   | If                the Parties are unable to agree on whether or not a recall or product                withdrawal is due to INEX’s negligence, willful misconduct or breach of                this Agreement, either Party may refer the matter for resolution                pursuant                to Article 13. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.3.4   | Notwithstanding                any expiration or early termination of this Agreement, the provisions                of                Sections 6.2 and 6.3 shall continue to apply for as long as any Product                containing Material that was sourced, Manufactured or quality released                by                INEX remains available for use in approved clinical                trials. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      7**
**INTELLECTUAL      PROPERTY RIGHTS**

**7.1  **
**Injunctive        Relief**

**7.2  **
**INEX        Title**

| 7.2.1   | the                assignments granted to Hana under this                Agreement; |
|-------------------|-------------------------------------------------------------------------------------|

| 7.2.2   | the                license granted to Hana under this                Agreement; |
|-------------------|---------------------------------------------------------------------------------|

| 7.2.3   | the                rights of the BCCA (including royalty obligations) under the BCCA                Agreements, in respect of the BCCA Patents;                and |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2.4   | the                rights of MD Anderson (including annual fee and royalty obligations)                under                the MD Anderson License in respect of the MD Anderson                Patents. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**7.3  **
**Ownership        of Pre-existing Intellectual Property Rights**

**7.4  **
**Ownership        of Future Intellectual Property Rights**

| 7.4.1   | Subject                to the Non-Competition Terms and any Notice of Abandonment that INEX                or                Hana may issue in respect of any Intellectual Property Rights related                to                the Products, all right, title and interest in and to any and all                Intellectual Property Rights that arise after the effective date                of this                Agreement and are related to the Products shall be owned as                follows:  |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | MD                Anderson and Hana shall be the joint owners of any patents and patent                applications filed after the effective date of this Agreement that                claim                priority to the Sarris Patents; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Hana                shall be the exclusive owner of any patents and patent applications                filed                after the effective date of this Agreement that claim priority to                the                Thomas Patents; and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | INEX                shall be the exclusive owner of any patents and patent applications                filed                after the Effective Date of the Definitive Agreements that claim                priority                to the Licensed Patents. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | All                Intellectual Property Rights of INEX existing before the effective                date of                this Agreement and all Intellectual Property Rights developed by                employees                or agents of INEX or its Affiliate solely or joint with a Third Party                after the effective date of this Agreement shall be and will remain                the                exclusive property of INEX, and subject to the grants of Sections                2.1 and                2.2. Notwithstanding any provisions to the contrary, this Agreement                does                not grant to Hana any right, title, or interest in or to any part                or whole                of the DHSM Patents referenced in Section 6.10 of the Transaction                Agreement, for which an option to license has been granted to                Hana; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | Subject                to Section 2.2, 7.4.1(a), 7.4.1(b), 7.4.1(c) and 7.4.1(d), all                Intellectual Property Rights conceived and reduced to practice solely                by                employees or agents of Hana or its Affiliate relating to the Products                shall be and remain the exclusive property of Hana and subject to                the                license grant of Section 2.2; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | Subject                to Sections 7.4.1(a), 7.4.1(b), 7.4.1(c) and 7.4.1(d), any Intellectual                Property Rights developed jointly by one or more employees or agents                of                each of INEX and Hana or their Affiliates relating to the Products                shall                be owned exclusively by Hana, and subject to the license grant of                Section                2.2; and |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (g)   | Each                Party shall ensure that its Representatives who perform any portion                of its                obligations under this Agreement have entered into written agreements                with                such Party whereby such Representatives assign to such Party all                ownership                rights in any Intellectual Property Rights made or developed by such                Representatives in the course of such work for such                Party. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 7.4.2   | Each                Party further agrees to execute, acknowledge and deliver to the requesting                Party such other instruments of conveyance and transfer and will                take such                other actions and execute, acknowledge and deliver such other documents,                certifications and further assurances as the requesting Party may                reasonably require in order to: (i) vest more effectively in the                requesting Party any rights transferred hereby, including but not                limited                to, obtaining registration or regulatory approval of any assets acquired                or rights granted hereunder or derivative works thereof; or (ii)                better                enable the requesting Party to exercise the rights acquired by such                Party                hereunder. Each of the Parties hereto will cooperate with the other                and                execute and deliver to the other Party such other instruments and                documents and take such other actions as may be reasonably requested                from                time to time by any other Party as necessary to carry out, evidence                and                confirm the intended purposes of this                Agreement. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.4.3   | Hana                agrees that in negotiating any joint venture, collaborative research,                development, Commercialization or other agreement(s) it may have                with any                Person other than INEX under which any Intellectual Property Rights                related to the Products may arise after the effective date of this                Agreement, Hana shall include in such agreements, provisions that                provide                for the assignment or license, as the case may be, of such Intellectual                Property Rights by such Person(s) and their Representatives to INEX                in                accordance with Sections 7.4.1(a), 7.4.1(b), 7.4.1(c) and                7.4.1(d). |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**7.5  **
**BCCA        Patents**

| 7.5.1   | The                Parties acknowledge that INEX has made Commercially Reasonable Efforts                to                obtain Aradigm’s consent to the assignment by INEX to Hana of the BCCA                Patents and has discharged its obligation under Section 6.7(a) of                the                Transaction Agreement. If Aradigm indicates its willingness to consent                to                such assignment and if Aradigm and the Parties are able to agree                upon the                terms and conditions for such assignment, the Parties will amend                this                Agreement and enter into such other legal documents reasonably necessary                to support the assignment of BCCA Patents to                Hana. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.5.2   | Notwithstanding                any expiration or termination of the Service Agreement dated April                3, 2007                between the Parties and notwithstanding that the assignment of BCCA                Patents do not constitute IP Services as defined herein, Hana shall                reimburse INEX’s out of pocket expenses, at cost, and INEX’s internal                costs at the FTE Rate, for all activities agreed between Hana and                INEX to                facilitate the assignment of the BCCA Patents to                Hana. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      8**
**PATENT      PROSECUTION AND MAINTENANCE**

**8.1  **
**IP        Committee**

**IP      Committee**

**8.2  **
**Responsibility        for Patent Prosecution and Maintenance**

----

| 8.2.1   | In                respect of all patents and patent applications that are listed in                **Exhibits                1.1.9 and 1.1.54**,                Hana shall be responsible for: |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | the                continued prosecution of any such pending patent applications to                the issuance of the resulting                patents; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | the                maintenance of all such issued Patents;                and |
|-----------------|-------------------------------------------------------------------------------|

| (c)   | the                filing of additional patent applications for such Patents in any                jurisdiction world-wide, including, without limitation, any continuations,                continuations-in-part, divisionals, patents of addition, reissues,                re-examinations and extensions of or substitutes therefore, which                additional patent applications (and resulting patents) shall be                automatically included in the Patents, and the provision of this                Article 8                shall apply thereto. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Exhibits      1.1.9 and 1.1.54**

| 8.2.2   | Notwithstanding                the allocation of patent prosecution and maintenance costs set forth                in                this Section 8.2, if Hana requests IP Services from INEX in respect                of any                activities which would otherwise have been performed by Hana pursuant                to                Section 8.2.1, INEX shall be entitled to payment of IP Services in                accordance with the provisions of Section 8.6 and the Service                Agreement. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.2.3   | Hana                shall be responsible for the prosecution of the pending patent                applications included in the Patents in accordance with the                responsibilities set forth in Section 8.2.1 and cost allocations                set forth                in **Exhibits                1.1.9 and 1.1.54**.                The cost allocations set out in **Exhibits                1.1.9 and 1.1.54**shall                be subject to review and amendment by mutual agreement of the Parties                on                an annual basis on or before December 31 of each year during the                Term. In                the event that the parties cannot reach agreement on or before December                31, the matter will be resolved by arbitration in accordance with                Article                13. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.2.4   | Hana                shall diligently pursue the prosecution of all patent applications                in                accordance with the responsibilities set forth in Section 8.2.1 and                cost                allocations set forth in **Exhibits                1.1.9 and 1.1.54**to                issuance of the resulting patents and shall not abandon, withdraw                or                discontinue prosecution of any pending patent applications included                in the                Patents without first consulting with and obtaining the prior written                consent of INEX, which consent shall not be withheld if the Parties                agree                that the issuance of a patent from such application is                unlikely. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.2.5   | At                the request of INEX, Hana shall diligently pursue and prosecute additional                patent filings relating to the Patents and Technology in any jurisdiction                worldwide in accordance with the responsibilities set forth in Section                8.2.1 and cost allocations set forth in **Exhibits                1.1.9 and 1.1.54**. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.2.6   | Either                Party may request the other Party to file new patent applications,                divisionals, provisionals, non-provisionals, continuations and                continuations-in-part to ensure that Valid Claims on Patents remain                pending. If the Party having primary responsibility for patent prosecution                and maintenance decides not to meet such request, the requesting                Party                shall be entitled to, at the requesting Party’s                election: |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | refer                the matter to arbitration pursuant to Article 13;                or |
|-----------------|------------------------------------------------------------------------------------------|

----

| (b)   | perform                such filings and take such actions as it deems necessary and at its                sole                cost. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | cooperate                with the requesting Party to perform such filings and take such actions                as                may be required by the requesting Party if the requesting Party does                not                have standing to perform such filings and take such actions;                or |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | grant                the requesting Party a power-of-attorney to perform such filings                and take                such actions as may be required by the requesting                Party; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**8.3  **
**Consultation**
**        and Reporting**

| 8.3.1   | On                a timely basis, Hana will consult with or instruct its patent agent(s)                and/or patent counsel(s) to consult with INEX, and INEX will consult                with                or instruct its patent agent(s) and/or patent counsel(s) to consult                with                Hana, regarding the claims and any proposed amendments thereto                of: |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | any                Patents pending and issued; and |
|-----------------|----------------------------------------------------|

| (b)   | any                additional patent applications to be included in the                Patents; |
|-----------------|-------------------------------------------------------------------------------------------------|

| 8.3.2   | On                a timely basis, Hana shall provide INEX with copies of the material                correspondence and documents which Hana sends or receives in connection                with the application, prosecution and maintenance of                Patents. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.3.3   | Provided                a Party has provided timely notice and copies of material correspondence                to the other Party of any matter requiring any action relating to                any                application, prosecution or maintenance of the Patents, the Party                providing timely notice shall not be found to be in breach of its                obligations under this Article 8 if the other Party, its patent agent(s)                and/or patent counsel(s) fail to consult with or provide written                instructions to the Party providing timely notice, at least five                (5)                Business Days prior to any deadline including an extendible deadline,                in                respect of any action required for the application, prosecution or                maintenance of the Patents. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**8.4  **
**Reports**

**8.5  **
**Abandonment,        Withdrawal or Discontinuance**

| 8.5.1   | Notwithstanding                each Party’s obligation under Section 8.2, should either Party decide                to: |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------|

| (a)   | discontinue                pursuing one or more patent applications, patent protection or patent                maintenance for one or more patents in relation to the Patents or                any                continuation, continuation-in-part, divisional, reissue, re-examination                or                extension thereof for any reason; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (b)   | not                pursue patent protection in relation to the Patents in any specific                jurisdiction for any reason; or |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | discontinue                or not pursue patent protection in relation to any further process,                use or                Product arising out of the Patents in any jurisdiction for any                reason; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Abandoning      Party**
**Non-Abandoning      Party**
**Notice      of Abandonment**

| 8.5.2   | The                Notice of Abandonment to be given by the Abandoning Party pursuant                to                Section 8.5.1 shall clearly identify the patent applications, patent                protection, and/or patent maintenance for the Patents to be                abandoned. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.5.3   | Each                of the Parties agrees that notwithstanding any provision to the contrary                in this Agreement, effective upon the date of the Non-Abandoning                Party’s                receipt of the Notice of Abandonment, the Abandoning Party shall                lose all                rights under: |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | the                patent(s) and patent application(s) to which such Party’s Notice of                Abandonment applies; and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | any                continuation, continuation-in-part, divisional, reissue, re-examination,                or extension of or to the                foregoing; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Discontinued      Patent**

| 8.5.4   | If                Hana gives Notice of Abandonment to INEX pursuant to Sections 8.5.1                and                8.5.2 in respect of: |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | one                or more of the Licensed Patents, this license shall be terminated                with                respect solely to such Discontinued Patent(s), and Hana shall forfeit                the                right to any and all uses of the Discontinued Patent(s) and Technology                claimed in such Discontinued Patent(s). **Exhibits                1.1.54**and**1.1.103**will                be deemed to be amended to exclude such Discontinued Patent and Technology                claimed in such Discontinued Patent from the grant of license contained                herein |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | one                or more of the Assigned Patents and INEX elects to continue to pursue                any                patent applications, patent protection and/or patent maintenance                in                relation to such Discontinued Patent in accordance with Section 8.5.5,                Hana shall forfeit the right to any and all uses of such Discontinued                Patent(s) and of the inventions and Technology claimed in such                Discontinued Patent(s), and assign such Discontinued Patent(s) to                INEX. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 8.5.5   | If                Hana has given Notice of Abandonment to INEX pursuant to Sections                8.5.1                and 8.5.2, and INEX wishes to continue to pursue any patent applications,                patent protection and/or patent maintenance in relation to Hana’s                Discontinued Patent: |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | within                ten (10) Business Days of INEX’s receipt of Hana’s Notice of Abandonment,                INEX shall provide Hana with written notice of INEX’s intention to pursue                any patent applications, patent protection and/or patent maintenance                in                relation to Hana’s Discontinued                Patent; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Hana                shall relinquish patent prosecution and maintenance of Hana’s Discontinued                Patent and INEX shall assume patent prosecution and maintenance of                same,                at INEX’s sole cost and expense;                and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | notwithstanding                the Non-Competition Terms, INEX shall have the exclusive right to                use                Hana’s Discontinued Patent and inventions claimed in Hana’s Discontinued                Patent, in the Hana Field. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.5.6   | If                INEX gives Notice of Abandonment to Hana pursuant to Sections 8.5.1                and                8.5.2 in respect of: |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | one                or more of the Licensed Patents, and Hana elects to continue to pursue                any                patent applications, patent protection and/or patent maintenance                in                relation to such Discontinued Patent in accordance with Section 8.5.7,                INEX shall forfeit the right to any and all uses of the Discontinued                Patent(s) and inventions claimed in any Discontinued Patent(s), and                shall                assign such Discontinued Patent(s) to                Hana. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | one                or more of the Assigned Patents, Hana’s grant of a license to INEX shall                be terminated with respect solely to the Discontinued Patent(s),                and INEX                shall forfeit the right to any and all uses of the Discontinued Patent(s)                and Technology claimed in such Discontinued Patent(s). **Exhibits                1.1.9**and                **1.1.103**will                be deemed to be amended to exclude such Discontinued Patent(s) and                Technology claimed in such Discontinued Patent(s) from the grant                of the                license to INEX contained herein. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.5.7   | If                INEX has given Notice of Abandonment to Hana pursuant to Sections                8.5.1                and 8.5.2 and Hana wishes to continue to pursue any patent applications,                patent protection and/or patent maintenance in relation to INEX’s                Discontinued Patent: |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | within                ten (10) Business Days of Hana’s receipt of INEX’s Notice of Abandonment,                Hana shall provide INEX with written notice of Hana’s intention to pursue                any patent applications, patent protection and/or patent maintenance                in                relation to INEX’s Discontinued Patent, at Hana’s sole cost and expense;                and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | notwithstanding                the Non-Competition Terms, Hana shall have the exclusive right to                use                INEX’s Discontinued Patent and the inventions claimed in INEX’s                Discontinued Patent, outside the Hana                Field. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.5.8   | Either                Party may request the other Party to perform such other Party’s                responsibilities set forth in Sections 8.2.1 or 8.2.2, as the case                may be,                in respect of a particular patent or patent application. If the Party                bearing such responsibility is unwilling or unable to perform its                responsibility in a timely manner, the Party requesting performance                in                respect of such patent or patent application may, with three (3)                days                prior written notice, perform the particular activity(ies) requested                in                respect of such patent or patent application. The Party unwilling                or                unable to perform its responsibility shall pay all reasonable costs                and                out-of-pocket expenses actually incurred by the requesting Party                to                perform the particular activity(ies) requested, within thirty (30)                days of                the non-performing Party’s receipt of the performing Party’s invoice for                such costs and out-of-pocket expenses. For the purposes of this Section                8.5.8, reasonable costs shall                be calculated using the FTE Rate set forth in the Service Agreement,                regardless of the Party performing the activity(ies), and notwithstanding                any termination of the Service                Agreement. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**8.6  **
**Costs        of Patent Application, Prosecution and Maintenance**

| 8.6.1   | Commencing                from the date that an Abandoning Party has lost all entitlement to                a                Discontinued Patent, such Abandoning Party shall not be required                to share                in any costs (and services fees if INEX is the Abandoning Party)                associated with the application, prosecution, and/or maintenance                of any                Patents in the Discontinued License                Patent. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.6.2   | Subject                to Section 8.6.1, and notwithstanding any termination of the Service                Agreement, for as long as INEX continues to perform at Hana’s request, the                activities required for intellectual property portfolio management                and all                associated activities including, without limitation, patent application,                filing, prosecution and maintenance, and payment of all government                and                legal fees required to apply for, prosecute and maintain the Patents                described in Section 8.2.1 (the “**IP                Services**”),                Hana, its successors, assigns or any Person(s) who acquires any interest                in any of the Patents and Technology will jointly and severally be                responsible for paying INEX: |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | [***]                percent ([***]%) of all reasonable out-of-pocket costs, including,                without                limitation, filing fees, fees for external counsel(s), patent agent(s),                contractors, travel, and lodging expenses incurred by INEX to provide                IP                Services; and |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | [***]                percent ([***]%) of the personnel costs incurred by INEX, calculated                at                INEX’s FTE Rate, pro rated to reflect the actual time employees,                contractors or consultants of INEX spend providing IP Services; provided                however, that on each anniversary of the Effective Date of the Definitive                Agreements, the FTE Rate shall be adjusted by a percentage equal                to the                percentage change in the Consumer Price Index (All Items) for the                province                of British Columbia for the twelve (12) month period ending with                December                of the calendar year immediately preceding such anniversary date;                and |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | [***]                percent ([***]%) of all out-of-pocket costs and [***] percent ([***]%)                of                all personnel costs incurred by INEX to provide IP Services in respect                of                any Discontinued Patent which Hana has elected to continue pursuing                patent                protection, pursuant to Section                8.5.5. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.6.3   | INEX                will invoice Hana monthly for all costs set forth in Section 8.6.2,                plus                all applicable taxes thereon, on or before the 30th                day after the end of the month in which the IP Services were rendered                and/or expenses incurred; provided however, that any out-of-pocket                costs                incurred which are not captured in any invoice may be captured in                subsequent invoices. Hana will pay all amounts due and payable hereunder                in full in Dollars to INEX within thirty (30) days of the date of                each                such invoice, by cheque or wire transfer to the account specified                by                INEX. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.6.4   | Notwithstanding                Section 8.6.3, during the Term, INEX shall not combine Hana’s payment                obligations for IP Services under the Service Agreement together                with                Hana’s payment obligations under this Section 8.6 to recover from Hana,                its successors, assigns or any Person(s) who acquires any interest                in any                of the Patents and Technology, more than the total monthly costs                set forth                in Section 8.6.2 in any given                month. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 8.6.5   | Hana                shall be responsible for prosecuting and maintaining the MD Anderson                Patents and for payment of all costs associated therewith. If INEX                exercises its rights under Section 2.2.1                to                either the Sarris Patents and/or the Thomas Patents, INEX shall be                responsible for ten percent (10%) of the cost of Hana’s prosecution and                maintenance of the Sarris Patents and/or the Thomas Patents, as                applicable. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**8.7  **
**Late        Payments**

| 8.7.1   | the                Prime Rate(s) during the period of late payment plus [***] percent                ([***]%) interest compounded monthly;                or |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.7.2   | the                maximum rate permitted by law; |
|-------------------|---------------------------------------------------|

**8.8  **
**Co-operation**

| 8.8.1   | making                available to the other Party or such other Party’s Representatives whom                the other Party in its reasonable judgment deems necessary in order                to                assist it in obtaining patent protection of the Patents;                and |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.8.2   | executing                and causing its Representatives to execute all legal documents reasonably                necessary to support the assignment, filing, prosecution and maintenance                of said Patents. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      9**
**INFRINGEMENT      PROCEEDINGS**

**9.1  **
**Limits**

| 9.1.1   | an                obligation by Hana or INEX to bring or prosecute or defend actions                or                suits against Third Parties for infringement of patents, copyrights,                trade-marks, industrial designs or other intellectual property or                contractual rights; or |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.1.2   | the                conferring by Hana or INEX of the right to use in advertising or                publicity                the name of Hana or INEX or their respective                trademarks. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**9.2  **
**Conduct        of Infringement Proceedings**

----

| 9.2.1   | an                alleged infringement by a Third Party of the Patents or Technology                or of                any right with respect to the Patents or Technology by the manufacture,                sale, services or use of products derived from the Patents or Technology                in the Hana Field; or |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.2.2   | any                complaint by Hana alleging any infringement by a Third Party with                respect                to the Patents or Technology or to any right with respect to the                Patents                or Technology by the manufacture, sale, service or use of products                derived                from the Patents or Technology in the Hana                Field; |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.2.3   | Hana                shall have the first right, in its sole discretion, and at its sole                expense, to prosecute or defend such                litigation; |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.2.4   | if                Hana does not take steps to prosecute or defend such litigation within                thirty (30) days after receipt of notice thereof, INEX may take such                legally permissible action as it deems necessary or appropriate to                prosecute such litigation or defend such litigation at its own expense,                but shall not be obligated to do                so; |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.2.5   | the                Party prosecuting or defending such litigation (in this Article,                the                “**Litigating                Party**”)                shall have the right to control such litigation and shall bear all                legal                expenses (including court costs and legal fees), including settlement                thereof provided however that no settlement or consent judgment or                other                voluntary final disposition of any suit defended or action brought                by a                Party pursuant to this Section 9.2 may be entered into without the                consent                of the other Party if such settlement would require the other Party                to be                subject to an injunction or to make a monetary payment or would restrict                the claims in or admit any invalidity of any Patents or significantly                adversely affect the rights of the other Party to this Agreement                (the                “**Non-litigating                Party**”).                By way of example and not by way of limitation, there shall be no                right of                the Litigating Party to stipulate or admit to the invalidity or                unenforceability of any Patents. Before any action is taken by the                Litigating Party which could abridge the rights of the Non-litigating                Party hereunder, the Parties agree to, in good faith, consult with                a goal                of adopting a mutually satisfactory                position; |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.2.6   | the                Non-litigating Party agrees to co-operate reasonably in any such                litigation to the extent of executing all necessary documents, supplying                essential documentary evidence and making essential witnesses then                in its                employment available and to vest in the Litigating Party the right                to                institute any such suits, so long as all the direct or indirect costs                and                expenses of bringing and conducting any such litigation or settlement                shall be borne by the Litigating Party, provided that INEX and Hana                shall                recover their respective actual out-of-pocket expenses, or equitable                proportions thereof, associated with any litigation or settlement                thereof                from any recovery made by any Party. Any excess amount remaining                after                satisfaction of the Parties’ recovery of their respective actual                out-of-pocket expenses, or equitable proportions thereof, associated                with                any litigation or settlement thereof from any recovery made by any                Party                (the “**Excess                Amount**”)                shall be shared between Hana and INEX on the same basis as set forth                in                Sections 3.1, 3.2 and 3.3 with respect to Royalties from Net Sales                of                Product in the applicable jurisdiction; provided however, that any                Excess                Amount in the form of punitive Damages shall be shared between Hana                and                INEX in proportion to each Party’s contribution to litigation expenses. In                the event a settlement or consent judgement does not distinguish                between                the forms of Damages payable by the Third Party, and Hana and INEX                cannot                agree on what portion, if any, of the Excess Amount constitutes punitive                Damages, the Parties will refer the matter to arbitration in accordance                with Article 13; |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 9.2.7   | the                Litigating Party shall keep the Non-litigating Party fully informed                of the                actions and positions taken or proposed to be taken by the Litigating                Party on behalf of itself or a licensee or sublicense (including                Licensee                or Sublicensee) and actions and positions taken by all other parties                to                such litigation; and |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.2.8   | in                the event that INEX prosecutes or defends such litigation, Hana may                elect                to participate formally in the litigation to the extent that the                court may                permit, but any additional expenses generated by such formal participation                shall be paid by Hana (subject to the possibility of recovery of                some or                all of such additional expenses as described in Section 9.2.6 or                from such                other parties to the litigation). |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**9.3  **
**Breach        of Confidence Proceedings**

**9.4  **
**Defense        of Infringement Proceedings**

| 9.4.1   | If                any complaint alleging infringement or violation of any patent or                other                proprietary rights is made against Hana, its Affiliate, Licensee                or                Sublicensee with respect to the Manufacture, use or sale of a Product,                the                following shall apply: |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | Hana                shall promptly notify INEX in writing upon receipt of any such complaint                setting out full details thereof and shall keep INEX fully informed                of the                actions and positions taken by the complainant and taken or proposed                to be                taken by Hana (on behalf of itself, a Licensee or a                Sublicensee); |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | if                such complaint gives rise to an indemnification obligation under                any of                the Definitive Agreements in favor of Hana (or its Affiliate or Licensee                or Sublicensee) on the part of INEX, then INEX shall defend such                suit and                all costs and expenses incurred by Hana (or any Affiliate or Licensee                or                Sublicensee) in investigating, resisting, litigating and settling                such a                complaint, including the payment of any award of Damages and/or costs                to                any Third Party, shall be paid by                INEX; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | if                such complaint does not give rise to an indemnification obligation                under                the Definitive Agreements in favor of Hana on the part of INEX, then                Hana                shall have the right but not the obligation to defend such suit and                all                costs and expenses incurred by Hana (or any Affiliate or Licensee                or                Sublicensee) in investigating, resisting, litigating and settling                such a                complaint, including the payment of any award of Damages and/or costs                to                any Third Party, shall be paid by Hana (or any Affiliate or Licensee                or                Sublicensee, as the case may be);                and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | in                any event, INEX and Hana shall assist one another and cooperate in                any                such litigation at each Party’s own                expense. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.4.2   | If                any complaint alleging infringement or violation of any patent or                other                proprietary rights is made against INEX, its Affiliate, licensee                or                sublicensee with respect to the Manufacture, use or sale of a Product,                the                following procedure shall apply: |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (a)   | INEX                shall promptly notify Hana in writing upon receipt of any such complaint                setting out full details thereof and shall keep Hana fully informed                of the                actions and positions taken by the complainant and taken or proposed                to be                taken by INEX; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | if                such a complaint gives rise to an indemnification obligation under                the                Definitive Agreements in favor of INEX on the part of Hana, then                Hana                shall defend such suit and all costs and expenses incurred by INEX                (or its                Affiliate) in investigating, resisting, litigating and settling such                a                complaint, including the payment of any award of Damages and/or costs                to                any Third Party, shall be paid by                Hana; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | if                such complaint does not give rise to an indemnification obligation                under                the Definitive Agreements in favor of INEX on the part of Hana, then                INEX                shall have the right but not the obligation to defend such suit and                all                costs and expenses incurred by INEX (or its Affiliate) in investigating,                resisting, litigating and settling such a compliant, including the                payment                of any award of Damages and/or costs to any Third Party, shall be                paid by                INEX; |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | in                any event, INEX and Hana shall assist one another and cooperate in                any                such litigation at each Party’s own                expense. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.4.3   | With                regard to costs and expenses incurred by Hana (or any Licensee or                Sublicensee) under Sections 9.4.1(c) or 9.4.2(b) in investigating,                resisting, litigating and settling such a complaint, including the                payment                of any award of Damages and/or costs to any Third Party (the “**Offset                Amount**”),                but not including any punitive award (the “**Punitive                Amount**”),                Hana (or any Licensee or Sublicensee) shall be entitled to offset                or                credit [***] percent ([***]%) of the Offset Amount against future                payments                otherwise due INEX as set forth in Section 3.7.1. With regard to                any                Punitive Amount (eg. willful infringement), the same is not included                in                the Offset Amount and is not to be offset or credited against future                payments due INEX. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.4.4   | In                the event a complaint is made under either of Sections 9.4.1 or 9.4.2,                no                settlement or consent judgment or other voluntary final disposition                may be                entered into without the consent of the other Party if such settlement                would require the other Party to be subject to an injunction or to                make a                monetary payment or would restrict the claims in or admit any invalidity                of any Patents or significantly adversely affect the rights of the                other                Party. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**9.5  **
**Co-operation        with Other Licensees**

| 9.5.1   | fields                outside of the Hana Field that may reasonably affect Hana’s use of the                Patents or Technology in the Hana Field or the Manufacture, use or                sale of                Product by Hana; or |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.5.2   | the                Hana Field that may reasonably affect INEX or one or more of INEX’s                sublicensee’s use of the Patents or Technology outside the Hana Field or                the manufacture, use or sale of products outside the Hana Field by                INEX or                one or more other such                sublicensee(s); |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**Article      10**
**CONFIDENTIAL      INFORMATION AND PUBLICATION**

**10.1  **
**Treatment        of Confidential Information**

| 10.1.1   | to                keep and use in strict confidence all Confidential Information of                the                other Party that each Party acquires, sees, or is informed of, as                a direct                or indirect consequence of this Agreement and to not, without the                prior                written consent of the other Party, disclose any such Confidential                Information or recollections thereof to any Person other than its                Representatives who are under an obligation of confidentiality on                terms                substantially similar to those set out in this Agreement, who have                been                informed of the confidential nature of the Confidential Information                and                who require such information in connection with the performance of                this                Agreement; |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.1.2   | that                all copies, duplicates, reproductions, translations or adaptations                of any                Confidential Information of the other Party made hereunder shall                be                clearly labeled as confidential;                and |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.1.3   | to                take all reasonable steps to prevent material in its possession that                contains or refers to Confidential Information of the other Party                from                being discovered, used or copied by Third Parties and that it shall                use                reasonable steps to protect and safeguard all Confidential Information                of                the other Party in its possession from all loss, theft or                destruction. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**10.2  **
**Permitted        Disclosures**

| 10.2.1   | where                in the reasonable and unqualified opinion of the receiving Party’s legal                counsel, disclosure is required to be made                under: |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | the                securities laws of any relevant jurisdiction, including the receiving                Party’s jurisdiction of incorporation or a jurisdiction in which the                receiving Party’s securities are traded on a stock exchange;                or |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | such                disclosure is required to be made by the receiving Party or its                Representatives under the terms of a valid and effective subpoena                or order                issued by a court of competent jurisdiction or by an administrative                body                or government authority; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | the                receiving Party shall immediately notify the disclosing Party prior                to any                such disclosure and the disclosing Party shall have been given the                opportunity where possible to oppose such disclosure by the receiving                Party by seeking a protective order or other appropriate remedy,                or to                waive compliance with the provisions of this                Agreement; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | the                receiving Party or its Representatives, as the case may be, shall                disclose                only that portion of the information legally required to be disclosed,                and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (e)   | the                receiving Party or its Representatives, as the case may be, will                exercise                all reasonable efforts to maintain the confidential treatment of                the                information; and |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.2.2   | to                Third Party contractors or collaborators to facilitate or carry out                the                Parties’ performance of their respective activities under this Agreement,                provided that such Third Parties enter into an agreement with such                Party                which contains confidentiality provisions substantially the same                as those                set forth herein. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**10.3  **
**Liability        for Representatives**

**10.4  **
**Publications**
**        Generally**

| 10.4.1   | at                least thirty (30) days before any proposed submission is submitted                and any                proposed publication is published by a Party (the “**Publishing                Party**”),                such Publishing Party shall provide the other Party with an advance                copy                of any such proposed submission or proposed publication, as the case                may                be, before any other disclosure of same and such other Party shall                have a                reasonable opportunity to recommend any changes it reasonably believes                are                necessary to preserve Intellectual Property Rights or Confidential                Information belonging in whole or in part to INEX or Hana, and the                incorporation of such recommended changes shall not be unreasonably                refused; and |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.4.2   | if                such other Party informs the Publishing Party, within thirty (30)                days                after receipt of an advance copy of a proposed publication, that                such                publication in its reasonable judgment could be expected to have                a                material adverse effect on any Intellectual Property Rights or                Confidential Information belonging in whole or in part to INEX or                Hana,                the Publishing Party shall delay or prevent such publication as proposed.                In the case of inventions, the delay shall be sufficiently long to                permit                the timely preparation and filing of a patent application(s) or                application(s) for a certificate of invention on the information                involved                but not more than ninety (90) days. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**10.5  **
**No        Limitation on Regulatory Compliance**

**10.6  **
**Return        of Confidential Information**

----

**Article      11**
**REPRESENTATIONS      AND WARRANTIES**

**11.1  **
**Hana        Representations and Warranties**

| 11.1.1   | Hana                is a corporation duly organised, existing, and in good standing under                the                laws of Delaware and has the power, authority, and capacity to enter                into                this Agreement and to carry out the transactions contemplated by                this                Agreement, all of which have been duly and validly authorised by                all                requisite corporate proceedings; |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.2   | the                execution, delivery and performance by Hana of this Agreement do                not                contravene or constitute a default under any provision of applicable                law                or its articles or by-laws (or equivalent documents) or of any judgment,                injunction, order, decree or other instrument binding upon                Hana; |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.3   | all                licenses, consents, authorizations and approvals, if any, required                for the                execution, delivery and performance by Hana of this Agreement have                been                obtained and are in full force and effect and all conditions thereof                have                been complied with, and no other action by or with respect to, or                filing                with, any governmental authority or any other Person is required                in                connection with the execution, delivery and performance by Hana of                this                Agreement; |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.4   | this                Agreement constitutes a valid and binding agreement of Hana, enforceable                against Hana in accordance with its terms, except as such enforceability                may be limited by bankruptcy, insolvency, moratorium or creditors’ rights                generally; |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.5   | the                execution, delivery and performance by Hana of this Agreement do                not and                will not conflict with or result in a material breach of any of the                terms                and provisions of any Third Party agreement of Hana entered into                as of the                effective date of this Agreement; |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.6   | Hana                is not aware of any impediment, including without limitation any                Third                Party agreement of Hana, which would prevent Hana from performing                its                obligations under this Agreement; |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.7   | Hana                will not enter into any Third Party agreement after the effective                date of                this Agreement which, in any way, will prevent Hana from performing                all of                the obligations hereunder; |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.8   | the                authorized capital of Hana consists of 100,000,000 shares of Common                Stock,                of which 29,295,117** **shares                are issued and outstanding as of March 30, 2007, and 10,000,000 shares                of                preferred stock, par value $0.001 per share, none of which is issued                and                outstanding. All of such issued and outstanding shares of Common                Stock                have been validly issued and are outstanding as fully paid and                non-assessable; |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.9   | the                issuance of the Common Stock has been duly authorized by all necessary                action on the part of Hana and no further action is required by Hana                or                its board of directors or shareholders to complete the issuance of                the                Common Stock; |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 11.1.10   | the                Common Stock, when issued, will be duly and validly issued, fully                paid and                non-assessable and will be free and clear of all liens, charges,                encumbrances and any rights of others. Hana has reserved from its                duly                authorized capital stock a number of shares sufficient to meet its                obligations to issue the Common Stock                hereunder; |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.11   | no                consent, approval, authorization or other order of any governmental                authority is required to be obtained by Hana in connection with the                authorization and issuance of Common Stock, except for such registrations,                filings or notices as have been made or as may be required to be                made                pursuant to U.S. or Canadian securities                laws; |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.12   | subject                to: (i) INEX’s representation and warranty set forth in Section 11.2.8;                and (ii) the completion of the assignment of the MD Anderson Patents                by                INEX to Hana, and to the best of the knowledge of Hana without independent                investigation or inquiry of any kind, Hana holds the entire right                title                and interest in and to the Assigned Patents, free and clear of all                encumbrances and Hana has the right and power to grant on an exclusive                and                non-exclusive basis, as the case may be, the licences granted to                INEX                under this Agreement without consent of any Third Party that may                claim any                such interest through Hana, including, without limitation, any secured                creditor of Hana |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.13   | subject                to INEX’s representation and warranty set forth in Section 11.2.9; and                subject to the completion of the assignment of the MD Anderson Patents                by                INEX to Hana, to the best of the knowledge of Hana without independent                investigation or inquiry of any kind, all the Assigned Patents are                validly                subsisting and all maintenance fees and similar annuity payments                have been                made in each of the jurisdictions requiring such payments;                and |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.14   | Subject                to INEX’s representation and warranty set forth in Section 11.2.12, and                without independent investigation or inquiry of any kind, except                for the                Intellectual Property Rights described in this Agreement, Hana neither                owns nor controls any Intellectual Property Rights that would be                required                by INEX in order to make, have made, use, sell, offer for sale, import,                and have imported Products outside the Hana Field in the                Territory. |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**11.2  **
**INEX        Representations and Warranties**

| 11.2.1   | INEX                is a corporation duly organised, existing, and in good standing under                the                laws of British Columbia and has the power, authority, and capacity                to                enter into this Agreement and to carry out the transactions contemplated                by this Agreement, all of which have been duly and validly authorised                by                all requisite corporate                proceedings; |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.2   | the                execution, delivery and performance by INEX of this Agreement do                not                contravene or constitute a default under any provision of applicable                law                or its articles or by-laws (or equivalent documents) or of any judgment,                injunction, order, decree or other instrument binding upon                INEX; |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.3   | all                licenses, consents, authorizations and approvals, if any, required                for the                execution, delivery and performance by INEX of this Agreement have                been                obtained and are in full force and effect and all conditions thereof                have                been complied with, and no other action by or with respect to, or                filing                with, any governmental authority or any other Person is required                in                connection with the execution, delivery and performance by INEX of                this                Agreement; |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 11.2.4   | this                Agreement constitutes a valid and binding agreement of INEX, enforceable                against INEX in accordance with its terms, except as such enforceability                may be limited by bankruptcy, insolvency, moratorium or creditors’ rights                generally; |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.5   | the                execution, delivery and performance by INEX of this Agreement do                not and                will not conflict with or result in a material breach of any of the                terms                and provisions of any Third Party agreement of INEX entered into                as of the                effective date of this Agreement; |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.6   | INEX                is not aware of any impediment, including without limitation any                Third                Party agreement, which would prevent INEX from performing its obligations                under this Agreement; |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.7   | INEX                will not enter into any Third Party agreement after the effective                date of                this Agreement which, in any way, will limit its ability to perform                all of                the obligations hereunder; |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.8   | to                the best of the knowledge of INEX, INEX holds the entire right title                and                interest in and to the Patents and Technology, free and clear of                all                encumbrances and INEX has the right and power to                grant: |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | on                an exclusive basis, the licences granted to Hana under this Agreement                without consent of any Third Party that may claim any such interest                through INEX, including, without limitation, any secured creditor                of INEX;                and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | the                assignments granted to Hana under this Agreement, and INEX has obtained                the consent of all Third Parties from whom consent to such assignments                is                required; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.9   | to                the best of the knowledge of INEX, all the Patents are validly subsisting                and all maintenance fees and similar annuity payments have been made                in                each of the jurisdictions requiring such                payments; |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.10   | to                the best of the knowledge of INEX, all statements contained in any                applications for the registration of the Patents were true and correct                as                of the date of such applications; |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.11   | except                for the Intellectual Property Rights described in this Agreement,                INEX                neither owns nor controls any Intellectual Property Rights that would                be                required by Hana in order to make, have made, use, sell, offer for                sale,                import, and have imported Products in the Hana Field in the Territory;                and |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.12   | to                the actual knowledge of INEX, without independent investigation or                inquiry, the rights to the Patents and Technology granted by INEX                pursuant                to this Agreement, are all of the Intellectual Property Rights necessary                for Hana to make, have made, use, sell, offer for sale, import, and                have                imported Products in the Hana Field within the Territory, without                any                infringement of or conflict with the Intellectual Property Rights                of Third                Parties. |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**11.3  **
**DISCLAIMER**

**Article      12**
**INDEMNIFICATION      AND LIABILITY LIMITATIONS**

**12.1  **
**Indemnification        by Hana**
** **

**INEX      Indemnitees**

| 12.1.1   | the                breach of any representation or warranty made by Hana                herein; |
|--------------------|-------------------------------------------------------------------------------------------------|

| 12.1.2   | the                default by Hana in the performance or observance of any of its obligations                to be performed or observed                hereunder; |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.1.3   | the                breach by Hana of any Regulatory Requirements, regulations and guidelines                in connection with any Product; |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------|

| 12.1.4   | any                complaint alleging infringement or violation of any patent or other                proprietary rights is made against INEX or its Affiliates with respect                to                Hana’s Manufacture, use or sale of a Product;                and |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.1.5   | any                injury or death to any Person or damage to any property caused by                any                Product provided by Hana or a Licensee or Sublicensee, whether claimed                by                reason of breach of warranty, negligence, product defect or otherwise,                and                regardless of the form in which any such claim is                made. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.1.6   | the                breach of any representation or warranty made by INEX                herein; |
|--------------------|-------------------------------------------------------------------------------------------------|

| 12.1.7   | the                default by INEX in the performance or observance of any of its obligations                to be performed or observed hereunder;                and |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.1.8   | the                breach by INEX of any Regulatory Requirements, regulations and guidelines                in connection with any Patents and                Technology. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**12.2  **
**Indemnification        by **
**INEX**

**Hana      Indemnitees**

----

| 12.2.1   | the                breach of any representation or warranty made by INEX                herein; |
|--------------------|-------------------------------------------------------------------------------------------------|

| 12.2.2   | the                default by INEX in the performance or observance of any of its obligations                to be performed or observed hereunder;                and |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.2.3   | the                breach by INEX of any Regulatory Requirements, regulations and guidelines                in connection with any Patents and                Technology; |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.2.4   | the                breach of any representation or warranty made by Hana                herein; |
|--------------------|-------------------------------------------------------------------------------------------------|

| 12.2.5   | the                default by Hana in the performance or observance of any of its obligations                to be performed or observed                hereunder; |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.2.6   | the                breach by Hana of any Regulatory Requirements, regulations and guidelines                in connection with any Product; and |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.2.7   | any                injury or death to any person or damage to any property caused by                any                Product provided by Hana or its Licensee or Sublicensees, whether                claimed                by reason of breach of warranty, negligence, product defect or otherwise,                and regardless of the form in which any such claim is                made. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**12.3  **
**Notice        of Claims**

**Indemnitee**
**Indemnitor**

| 12.3.1   | the                Indemnitor is granted, subject to the provisions of this Section                12.3 and                the relevant provisions of Article 9, full authority and control                over the                defense, including settlement, against such claim or law suit or                other                action, and |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.3.2   | the                Indemnitee cooperates fully with the Indemnitor and its agents in                defense                of the claims or law suit or other                action. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**12.4  **
**Consequential        Losses**

**12.5  **
**Actions        Between the Parties**

**12.6  **
**Insurance**

| 12.6.1   | Prior                to or immediately upon the start of any human clinical trials or                other                product testing involving human subjects by Hana or its Licensee                or                Sublicensee (“**Human                Clinical Trials**”)                and for a period of five (5) years after the expiration of this Agreement                or the earlier termination thereof, Hana shall obtain and/or maintain,                respectively, at its sole cost and expense, public liability and                product                liability insurance in not less than the following amounts, with                a                reputable and financially secure insurance                carrier: |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | Each                Occurrence:$5,000,000                Dollars |
|-----------------|------------------------------------------------------------------|

| (b)   | General                Aggregate:$5,000,000                Dollars |
|-----------------|--------------------------------------------------------------------|

| 12.6.2   | At                all times during the Term of this Agreement and for a period of five                (5)                years after the expiration of this Agreement or the earlier termination                thereof, INEX shall obtain and/or maintain, respectively, at its                sole cost                and expense, comprehensive or commercial form general liability coverage,                including contractual liability, and public liability insurance in                not                less than the following amounts, with a reputable and financially                secure                insurance carrier: |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | Each                Occurrence:$4,000,000                (Canadian dollars) |
|-----------------|-----------------------------------------------------------------------------|

| (b)   | General                Aggregate:$4,000,000                (Canadian dollars) |
|-----------------|-------------------------------------------------------------------------------|

----

| 12.6.3   | Each                Party shall require that such Party’s Representatives and Hana’s Licensee                and Sublicensee under this Agreement shall                either: |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | demonstrate                to the other Party’s reasonable satisfaction that such Representative or                Hana’s Licensee or Sublicensee has a program of self insurance no less                adequate than that which a reasonable and prudent businessperson                carrying                on a similar line of business would require;                or |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | sixty                (60) days prior to the earlier of the start of Human Clinical Trials                or                the first sale of any such Product by Hana’s Licensee or Sublicensee,                procure and maintain public liability and product liability insurance                in                reasonable amounts, with a reputable and financially secure insurance                carrier. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.6.4   | Notwithstanding                anything to the contrary contained in this Section 12.6, before the                first                date of commercial sale of any Product in the U.S., Hana and its                Affiliate                and Licensee and Sublicensee of each such Product will maintain in                full                force and effect, with reputable insurers or pursuant to a self-insurance                program, product liability insurance to a minimum value of Five                Million Dollars ($5,000,000) per each occurrence and in the                aggregate. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      13**
**DISPUTE      RESOLUTION**

**13.1  **
**Negotiation        and Arbitration**

| 13.1.1   | Prior                to engaging in any formal dispute resolution with respect to any                dispute,                controversy or claim arising out of or in relation to this Agreement                or                the breach, termination or invalidity of this Agreement (each, a                “**Dispute**”),                the Chief Executive Officers of the Parties shall attempt to resolve                the                Dispute for a period not less than thirty (30)                days. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.1.2   | Except                for any Dispute with respect to Intellectual Property Rights, which                may,                at the option of the other Party, be dealt with by commencing an                action in                a court of competent jurisdiction, any Dispute that cannot be settled                amicably by agreement of the Parties pursuant to Section 13.1.1 may,                on                mutual agreement of the Parties, be finally settled by a single arbitrator                appointed pursuant to the rules of The Center for Public Resource’s                Institute for Dispute Resolution. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.1.3   | The                place of arbitration shall be Seattle, Washington and the language                to be                used in the arbitration proceedings shall be                English. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.1.4   | The                award rendered in any arbitration shall be final and binding upon                both                Parties. The judgment rendered by the arbitrator(s) shall include                costs of                arbitration, reasonable legal fees and reasonable costs for any expert                and                other witnesses. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.1.5   | Nothing                in this Agreement shall be deemed as preventing either Party from                seeking                specific performance, injunctive relief (or any other equitable relief),                in respect of any actual or threatened breach of this Agreement,                without                proof of actual damages, from any court having jurisdiction over                the                Parties and the subject matter of the Dispute as necessary to protect                either Party’s name, Confidential Information or Intellectual                property. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 13.1.6   | Notwithstanding                the provisions of Subsections 13.1.2 through 13.1.5 inclusive, either                Party shall be free to submit any Dispute relating to Intellectual                Property Rights to any court having jurisdiction over the Parties                and the                subject matter of the Dispute and to seek such relief and remedies                as are                available in that court. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.1.7   | Each                Party is required to continue to perform its obligations under this                Agreement pending final resolution of any                Dispute. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      14**
**TERM      & TERMINATION**

**14.1  **
**Term**

| 14.1.1   | The                license grant by INEX to Hana in this Agreement shall become effective                on                the effective date of this Agreement and, unless earlier terminated                in                accordance with this Article 14, shall expire, on a country-by-country                basis, in respect of each Product upon the later                of: |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | expiration                of the last to expire of the Patents containing Valid Claims covering                such                Product in such country in the Territory; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | expiration                of the last to expire period of product exclusivity covering such                Product                that is provided by the laws of such country in the Territory;                and |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | on                the date that all Technology cease to be Confidential Information                under                the circumstances set out in Section                1.1.24. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Term**

**14.2  **
**Termination        for Invalidity Challenge**

| 14.2.1   | Hana                will not less than sixty (60) days prior to making any such assertion,                provide to INEX a complete written disclosure of each and every basis                then                known to Hana or its Affiliate for such assertion and, with such                disclosure, will provide INEX with a copy of any document or publication                upon which Hana or its Affiliate intends to rely in support of such                assertion; and. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.2.2   | INEX                shall be entitled, upon not less than thirty (30) days prior written                notice to Hana, to terminate the license granted to Hana under Article                2                or require an assignment by Hana to INEX of such Assigned Patent                (as the                case may be) for such Product(s) covered by the patent under challenge                in                the applicable jurisdiction; provided however, that INEX shall not                terminate such license or require assignment of such Assigned Patent                (as                the case may be) if within thirty (30) days of Hana’s receipt of INEX’s                notification hereunder, Hana has: |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | confirmed                by written notice to INEX that Hana no longer intends to challenge                the                validity or enforceability of any Patent;                or |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (b)   | provided                to INEX, documentation to confirm Hana’s withdrawal of its filing,                submission or other process commenced in any court or other governmental                agency of competent jurisdiction to challenge the validity or                enforceability of any Patent. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**14.3  **
**Termination        on Bankruptcy**

| 14.3.1   | This                Agreement may be terminated by INEX by providing written notice to                Hana                upon: |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------|

| (a)   | the                bankruptcy, liquidation or dissolution of                Hana; |
|-----------------|-----------------------------------------------------------------------------------|

| (b)   | the                filing of any voluntary petition for bankruptcy, dissolution, liquidation                or winding-up of the affairs of Hana;                or |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | the                filing of any involuntary petition for bankruptcy, dissolution,                liquidation or winding-up of the affairs of Hana which is not dismissed                within one hundred twenty (120) days after the date on which it is                filed                or commenced. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.3.2   | This                Agreement may be terminated by Hana by providing written notice to                INEX                upon: |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------|

| (a)   | the                bankruptcy, liquidation or dissolution of                INEX; |
|-----------------|-----------------------------------------------------------------------------------|

| (b)   | the                filing of any voluntary petition for bankruptcy, dissolution, liquidation                or winding-up of the affairs of INEX;                or |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | the                filing of any involuntary petition for bankruptcy, dissolution,                liquidation or winding-up of the affairs of INEX which is not dismissed                within one hundred twenty (120) days after the date on which it is                filed                or commenced. Notwithstanding the bankruptcy of INEX, or the impairment                of                performance by INEX of its obligations under this Agreement as a                result of                bankruptcy of INEX, to the extent that INEX retains the rights necessary                to grant the licenses granted in this Agreement, Hana shall be entitled                to                retain the licenses granted herein, subject to INEX’s rights to terminate                this Agreement as provided in this                Agreement. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.3.3   | In                the event INEX shall: (1) make an assignment for the benefit of creditors,                or petition or apply to any tribunal for the appointment of a custodian,                receiver, or trustee for all or a substantial part of its assets;                (2)                commence any proceeding under any bankruptcy, dissolution, or liquidation                law or statute of any jurisdiction whether now or hereafter in effect;                (3)                have had any such petition or application filed or any such proceeding                commenced against it in which an order for relief is entered or an                adjudication or appointment is made, and which remains undismissed                for a                period of one hundred twenty (120) calendar days or more; (4) take                any                corporate action indicating its consent to, approval of, or acquiescence                in any such petition, application, proceeding, or order for relief                or the                appointment of a custodian receiver, or trustee for all or substantial                part of its assets; or (5) permit any such custodianship, receivership,                or                trusteeship to continue undischarged for a period of one hundred                twenty                (120) calendar days or more (each, a “**Bankruptcy                Action**”),                and the occurrence of any of the foregoing causes the applicable                Party or                any Third Party, including, without limitation, a trustee in bankruptcy,                to be empowered under state or federal law to reject this Agreement                or any                Agreement supplementary hereto, then Hana shall have the following                rights: |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (a)   | in                the event of a rejection of this Agreement or any agreement supplementary                hereto, Hana shall be permitted to receive and use any Technology                and                Confidential Information for the purpose of enabling it to mitigate                damages caused to Hana because of the rejection of this                Agreement; |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | in                the event of a rejection of this Agreement or any Agreement supplementary                hereto, Hana may elect to retain its rights under this Agreement                or any                agreement supplementary hereto as provided in Section 365(n) of the                United                States Bankruptcy Code or comparable provision of the laws of any                other                country in the Territory. Upon Hana’s written request to INEX or the                bankruptcy trustee or receiver, INEX or such bankruptcy trustee or                receiver shall not interfere with the rights of Hana as provided                in this                Agreement or in any agreement supplementary                thereto; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | in                the event of a rejection of this Agreement or any Agreement supplementary                hereto, Hana may elect to retain its rights under this Agreement                or any                agreement supplementary hereto as provided in Section 365(n) of the                United                States Bankruptcy Code or comparable provision of the laws of any                other                country in the Territory without prejudice to any of its rights of                setoff                and/or recoupment with respect to this Agreement under the Bankruptcy                code                or applicable non-bankruptcy law;                or |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | in                the event of a rejection of this Agreement or any Agreement supplementary                hereto, Hana may retain its rights under this Agreement or any agreement                supplementary hereto as provided in Section 465(n) of the United                States                Bankruptcy Code or comparable provision of the laws of any other                country                in the Territory without prejudice to any of its rights under Section                503(b) of the Bankruptcy Code or comparable provision of the laws                of any                other country in the Territory. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | INEX                will provide Hana with thirty (30) days prior written notice of INEX’s                regulatory filings in respect of any reorganization or arrangement                proposed by INEX; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | any                reorganization or arrangement involving INEX, its affiliates and/or                its                wholly owned subsidiaries which does not prejudice the rights of                Hana                shall not constitute a Bankruptcy Action for the purposes of this                Section                14.3.3 and shall not give rise to the remedies set forth in this                Section                14.3.3; and |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (g)   | if                Hana asserts any rights under Section 14.3.3(a), 14.3.3(b), 14.3.3(c)                or                14.3.3(d), Hana shall continue to be bound by all liabilities and                obligations imposed upon Hana, its Affiliates, Licensees and Sublicensees,                any remedies available to INEX under this                Agreement. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**14.4  **
**Termination**
**        for Material Breach**

| 14.4.1   | Except                as otherwise provided in this Agreement, either Party shall be entitled                to                terminate this Agreement by written notice to the other Party in                the event                that the other Party is in material breach of its obligations hereunder                and fails to remedy any such breach within ninety (90) days after                notice                thereof by the Party alleging breach. Any such notice                shall: |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (a)   | specifically                state that the Party not in default intends to terminate this Agreement                in                the event that the other Party fails to remedy the breach;                and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | expressly                set forth the actions required of the other Party to remedy the                breach. |
|-----------------|-----------------------------------------------------------------------------------------------------------------|

| 14.4.2   | If                a Dispute arises as to whether either Party is in material breach                of its                obligations hereunder, or as to whether such Party has cured any                such                breach, either Party may invoke the dispute resolution procedure                described                in Article 13 to resolve such                Dispute. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**14.5  **
**No        Limitation on Remedies**

**14.6  **
**Consequences        of Termination**

| 14.6.1   | Notwithstanding                anything to the contrary herein, if INEX terminates this Agreement                pursuant to this Article 14, within thirty (30) days following the                effective date of such termination, Hana shall assign to                INEX: |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | Hana’s                entire right, title and interest in and to the Thomas Patents subject                to                the terms and conditions set forth in the MD Anderson License;                and; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Hana’s                entire right, title and interest in and to Hana’s joint ownership of the                Sarris Patents subject to the terms and conditions set forth in the                MD                Anderson License. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.6.2   | Upon                any termination by INEX of the licenses granted by INEX or of this                Agreement: |
|--------------------|------------------------------------------------------------------------------------------------------------------|

| (a)   | Hana                shall not be relieved of any obligations incurred prior to such                termination; |
|-----------------|-----------------------------------------------------------------------------------------------------------------|

| (b)   | each                Party shall promptly return to the other Party all written Confidential                Information, and all copies thereof (except for one archival copy                to be                retained solely for the purpose of confirming which information to                hold in                confidence hereunder); and |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | all                Licenses and Sublicenses granted hereunder shall forthwith                terminate. |
|-----------------|---------------------------------------------------------------------------------------------------------|

----

| 14.6.3   | The                termination by INEX of the licenses granted by INEX or of this Agreement                will be without prejudice to: |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | INEX’s                right to receive all payments accrued from Hana pursuant to Section                8.6 as                of the effective date of such termination including, without limitation,                payment for all out-of-pocket costs and personnel costs which INEX                has                properly and reasonably incurred in providing IP Services and in                following                instructions received from Hana up to the date of such termination.                For                greater certainty, such costs shall include INEX’s reasonable and                necessary non-cancelable obligations to Third Parties actually incurred                by                INEX in the performance if its obligations under this Agreement prior                to                the date of notice of termination, but arising after the date of notice of                termination; and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | any                other legal, equitable or administrative remedies as to which either                Party                may then or thereafter become                entitled. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**14.7  **
**Disposition        of Product**

**14.8  **
**Delivery        of Data and Materials and License**

| 14.8.1   | Provided                that INEX shall be responsible for any reasonable associated out-of-pocket                costs associated with the following activities, Hana shall deliver                to INEX                a copy of all data (including animal and human) and such other                information, Materials, materials (including biological materials)                and                documents in Hana’s possession or control arising from the Development of                Product under this Agreement that INEX may reasonably require in                order to                obtain and/or maintain Regulatory Approvals for such Product in the                applicable country(ies). INEX may, directly or through a licensee,                exploit                such data, other information, Materials, materials (including biological                materials) and documents to develop, make, have made, import, use,                offer                for sale and sell Product in such                countries. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.8.2   | Hana                shall also, within thirty (30) days after the effective date of such                termination, use all reasonable endeavors to take all steps and execute                all documents reasonably necessary to assign and/or transfer or permit                reference to (to the extent legally permissible in the relevant country)                all Regulatory Submissions and Regulatory Approvals arising from                the                Development of Product under this Agreement in Hana's name or in                the name                of Hana's Representatives to INEX or its designee, provided that                INEX                shall be responsible for any reasonable associated out-of-pocket                costs of                transfer. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 14.8.3   | In                the event that no such assignment and/or transfer and/or reference                pursuant to Section 14.8.2 may legally be made, then Hana shall forthwith                surrender to INEX or its designee such Regulatory Submissions and                Regulatory Approvals for                cancellation. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.8.4   | Upon                INEX’s request, Hana shall within thirty (30) days after the effective                date of such termination, deliver to INEX or its designee any and                all                documents relating to applications, correspondences with Regulatory                Authorities, Regulatory Submissions, Regulatory Approvals, and                post-Regulatory Approval Pharmacovigilance in its possession or control                arising from the Development of Product that are reasonably required                for                Commercialization of Product in such country(ies), provided that                INEX                shall be responsible for any reasonable associated out-of-pocket                costs of                transfer. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      15**
**GENERAL      PROVISIONS**

**15.1  **
**Amendments**

**15.2  **
**Assignment**

**15.3  **
**Counterparts;        Facsimile**

**15.4  **
**Entire        Agreement**

**15.5  **
**Enurement**

----

**15.6  **
**Exhibits**

**15.7         **
**Force        Majeure**

**15.8  **
**Further        Assurances**

**15.9  **
**Governing        Law**

**15.10  **
**Headings**

**15.11  **
**Independent        Legal Advice**

**15.12  **
**International        Sale of Goods Act**

**15.13  **
**Jurisdiction**

----

**15.14  **
**Non-Use        of Names**

**15.15  **
**Notices**

| If                to Hana:Hana                BioSciences, Inc.7000                Shoreline Court, Suite 370,South                San Francisco, CA 94080U.S.A Attention:                President and/or C.E.O. Tel: Fax:                                                                                                     |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| If                to INEX: Inex                Pharmaceuticals Corporation#200                - 8900 Glenlyon ParkwayBurnaby,                B.C.Canada                V5J 5J8 Attention:                 President                and/or C.E.O. Tel: (604)                419-3200Fax: (604)                419-3201 |   |

**15.16  **
**No        Implied Rights**

----

**15.17  **
**No        **
**Solicitation        or Hiring of Employees**

**15.18  **
**No        Third-Party Rights**

**15.19  **
**No        Waiver**

**15.20  **
**Publicity**

| 15.20.1   | neither                Party, nor any of its Affiliates, shall originate any publicity,                news                release or other public announcement, written or oral, relating to                this                Agreement or the existence of an arrangement between the Parties,                without                the prior written approval of the other Party and agreement upon                the                nature and text of such announcement or disclosure, which approval                shall                not be unreasonably withheld or delayed;                and |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 15.20.2   | the                Party desiring to make any such public announcement or other disclosure                shall inform the other Party of the proposed announcement or disclosure                in                reasonably sufficient time prior to public release, and shall provide                the                other Party with a written copy thereof, in order to allow such other                Party to comment upon such announcement or                disclosure. |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**15.21  **
**Relationship        of Parties**

**15.22  **
**Rights        and Remedies**

----

**15.23  **
**Severability**

| 15.23.1   | such                provision shall be severable from the remainder of the Agreement                in the                jurisdiction in which such provision was found to be invalid, illegal                or                unenforceable; |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 15.23.2   | the                validity, legality and enforceability of such provision will not                in any                way be affected or impaired thereby in any other jurisdiction and                the                validity, legality and enforceability of the remaining provisions                contained herein will not in any way be affected or impaired thereby,                unless in either case as a result of such determination this Agreement                would fail in its essential purpose;                and |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 15.23.3   | the                Parties will use their best efforts to substitute for any provision                that                is invalid, illegal or unenforceable in any jurisdiction a valid,                legal                and enforceable provision which achieves to the greatest extent possible                the economic, legal and commercial objectives of such invalid, illegal                or                unenforceable provision and of this                Agreement. |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**15.24  **
**Survival**
** **

**15.25  **
**Wording**

| **HANA**                                             | **INEX              PHARMACEUTICALS**                |
|------------------------------------------------------|------------------------------------------------------|
| **BIOSCIENCES, INC.**                                | **CORPORATION**                                      |
| by its authorized signatory:                         | by its authorized signatory:                         |
|                                                 |                                                 |
| /s/ Mark J. Ahn                                      | /s/ Timothy Ruane                                    |
| Mark J. Ahn                                          | Timothy Ruane                                        |
| President                and Chief Executive Officer | President                and Chief Executive Officer |

----